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General Introduction  11 
Undifferentiated and Rheumatoid Arthritis 
Arthritis is a group of conditions characterized by inflammation of the joints. This 
inflammation can lead to breakdown of the cartilage of the joints that can be caused by 
different mechanisms, e.g. autoimmunity, fractures, wearing, or infection. The different 
types of arthritis are diagnosed according to disease criteria, leaving cases that cannot 
be classified in one of the accepted categories of rheumatic diseases (usually referred to 
as ‘undifferentiated arthritis’ (UA)). The diagnosis of rheumatoid arthritis (RA), an 
inflammatory autoimmune disorder characterized by a chronic inflammation of the 
synovial tissue of several joints, is based on a list of seven criteria developed by the 
American College of Rheumatology (1). These criteria include clinical, radiological 
and laboratory findings; i.e. morning stiffness, arthritis of three or more joint areas, 
arthritis of hand joints, symmetric arthritis, serum rheumatoid factor, rheumatoid 
nodules, and radiographic changes. The RA patient population is clinically hetero-
geneous since only four of these seven ACR criteria have to be fulfilled for the 
diagnosis of RA. The occurrence of RA varies among countries and areas over the 
world, but has a prevalence of approximately 1% in Europe (2;3). In the Dutch 
population, women are affected by RA approximately two times more frequently than 
men (4). 
In the Leiden Early Arthritis Clinic (EAC), which provides an inception cohort of 
patients with recent onset arthritis (5), 37% of the patients are diagnosed with UA and 
about 20% with RA at their first visit. After 1 year, 32% of the UA patients have 
qualified for the diagnosis of RA, indicating the complexity of a diagnosis at initial 
presentation. 
 
RA patients can develop different kind of autoantibodies, amongst others against 
citrullinated proteins (anti-citrullinated protein antibodies (ACPA)). Citrullination is a 
post-translational conversion (deimination) of Arginine to Citrulline residues per-
formed by the enzyme peptidylarginine deiminase (PAD) (Figure 1) that results in a 
small change in molecular mass (<1 Da) and the loss of one positive charge. Although 
citrullination is a common natural process, these ACPA are specific for RA, and can be 
measured already years before symptomatic disease (6;7). Recently, it has been shown 
that ACPA+ and ACPA- RA patients show a different disease course, probably 
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Progression and Severity scoring 
RA is characterized by the proliferation of synovium and the destruction of cartilage 
and bone during the progression of the disease. Destruction of the cartilage is a 
consequence of pro-inflammatory cytokines and enzymes that are released during the 
chronic inflammation process inducing enhanced breakdown of cartilage matrix and 
reduced synthesis of matrix components by the articular chondrocytes (11;12), but joint 
erosion results more directly from osteoclasts (13). The formation of pannus, which 
results from the proliferating synovium (14-16), will eventually lead to joint space 
narrowing and joint erosions. This is, at least in part, mediated by fibroblast-like 
synoviocytes from the synovium (17). 
Radiographic joint damage is an important outcome measure in RA, in addition to 
assessments of physical function and disease activity, which all associate with each 
other (18). It reflects cumulative disease activity and is related to overall disability 
(19;20). Therefore, progression rates are also influenced by the current therapy, i.e. 
disease modifying anti-rheumatic drugs (DMARDs) (21;22). Several scoring methods 
for the assessment of radiographic joint damage exist, from which the most well known 
are the Larsen (23) and Sharp-van der Heijde method (24;25). Both methods score the 
individual joints of the extremities but the Sharp-van der Heijde method scores hands 
and feet for the amount and severity of erosions and joint space narrowing separately 
(25). The Sharp-van der Heijde method is sensitive to detect changes over time and 
shows reliable results since it has a low measurement error (26). Analyses of 
radiographic progression can be analyzed on the individual patient or a patient group 
level. For both applies that the radiological progression is linear in the first 
Figure 1. Citrullination. An Arginine residue is enzymatically converted by 
peptidylarginine deiminase (PAD) into a Citrulline residue in the presence of Ca2+. 
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(approximately) five years but further in time, the curve levels off to a plateau (18;27-
29). 
Because nowadays, RA patients are seen in an earlier phase of the disease, before the 
appearance of well established indicators of poor prognosis such as erosions and 
nodules, markers which have a good predictive value on radiographic damage in an 
early phase of the disease will become more important. 
 
Genetic Risk Factors for RA 
The pathogenesis of RA is, as in many other autoimmune diseases, complex and 
largely unknown. It is generally accepted that both genetic and environmental factors 
contribute and probably also interact with each other. It has been described that genetic 
factors contribute for about 2/3 to the development of RA (30;31). The contributing 
risk factors can differ for the susceptibility to, and the progression of RA. 
The strongest genetic risk factor, both for susceptibility and severity, has been mapped 
to the HLA-class II region, most probably DRB1. HLA-class II molecules consist of an 
- and -chain which both have constant and variable regions. The variable regions 
constitute the binding groove for the peptide to be presented by HLA molecules to T 
cells of the immune system (Figure 2). A particular part of the binding groove, the 
third hypervariable region, is involved in the susceptibility to RA development. At 
position 70 to 74 in this third hypervariable region, different variants of amino acid 
sequences are present. Certain HLA-DRB1 alleles share common epitopes at this 
position. Regarding the risk for RA development, three variants can be discriminated; 
either amino acids of the so-called shared epitope (SE), the sequence “DERAA”, or 
‘neutral’ amino acids are present. Compared to the ‘neutral’ HLA-DRB1 alleles, 
carriership of HLA-DRB1 alleles with the SE increases the risk for RA development, 
and “DERAA”-containing HLA-DRB1 alleles decrease the risk. Both the SE and the 
























Shared Epitope and ACPA 
HLA-DRB1 molecules containing the amino acid sequence R(Q)K(R)RAA (i.e. the 
amino acids Arginine, (Glutamine), Lysine, (Arginine), Arginine, Alanine, Alanine) at 
position 70-74 in the third hypervariable region are belonging to the Shared Epitope 
(SE) alleles. This epitope is present in the HLA-DRB1*0101, *0102, *0401, *0404, 
*0405, *0408, *0410, *1001 and *1402 alleles. The SE is associated with an increased 
risk (about 2.5 times (33)) to develop RA and a more severe disease course. It is 
postulated that this SE sequence, which is present in the binding cleft of the HLA-DR 
molecule, is directly related to the binding of RA inducing peptides to the SE-
containing HLA-DR molecules. These peptides are then presented to T cells thought to 
play an important role in the pathogenesis of RA. Since there is high linkage 
disequilibrium between HLA-DRB1 and HLA-DQB1 alleles, it is also hypothesized 
that the HLA-DQB1 alleles are associated with RA susceptibility, although these 
associations cannot be distinguished (34-36). RA-inducing peptides are not identified 
yet, but several findings indicate new directions for epitope discovery. Recently it has 
been shown that SE-containing HLA-DRB1 alleles do not confer risk to the 
development of RA itself, but predispose to the development of anti-citrullinated 
protein antibodies (ACPA). These antibodies are highly predictive for RA development 
as discussed in a previous section (6;7). ACPA+ UA Patients have approximately 
Figure 2. HLA class II molecule (adapted from Boots et al. (32)). The variable regions 
of the - and -chain build up the peptide binding groove. The rectangle indicated in the 
figure shows the position of the third hypervariable region (HVR) where the shared 
epitope (SE) or “DERAA”-sequence can be present. 
3rd HVR position 70-74: 
SE or DERAA can be present
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fifteen times higher odds to develop RA within one year compared to ACPA- UA 
patients. These ACPA are commonly measured in the IgG isotype, but are also present 
in the IgM and IgA isotype (37).  
The presence of IgG ACPA indicates the presence of T cell help. One of the proteins 
described to be citrullinated in vivo and present in the synovial fluid of RA patients is 
the cytoskeletal protein vimentin (38;39). We have recently shown that 90% of ACPA+ 
RA patients recognizing a citrullinated peptide derived from vimentin carry one or two 
SE-containing HLA-DRB1 alleles (40), suggesting the involvement of helper T cells 
recognizing a citrullinated epitope from vimentin in the context of the SE-containing 
HLA-DRB1 alleles. The identification of citrullinated vimentin-derived T cell epitopes 
recognized by HLA-DR4 positive individuals is described in Chapter 4 of this thesis. 
“DERAA” 
“DERAA” stands for the amino acid sequence of Aspartic acid-Glutamic acid-
Arginine- Alanine-Alanine which is present in the HLA-DRB1 alleles of the subtype 
HLA-DRB1*0103, *0402, *1102, *1103, *1301, *1302 and *1304. These alleles are 
present in 29% of the population (33;41-43).It has been shown by several groups that 
the frequency of “DERAA”-containing HLA-DRB1 alleles is reduced in RA patients 
compared to healthy controls and that the risk to develop RA is reduced by about 40% 
in DERAA positive individuals (33). Since the “DERAA” sequence is positioned at the 
same location as the SE in the HLA-DRB1 molecule, the effect of “DERAA” has to be 
evaluated after stratification for presence of the SE-containing HLA-DRB1 alleles. In 
this way, it has been shown that the effect of “DERAA”-containing HLA-DRB1 alleles 
is independent of the SE-containing HLA-DRB1 alleles (33). 
 
“DERAA”-containing HLA-DRB1 alleles can be inherited, but can also be conferred 
as non-inherited maternal antigens (NIMA). NIMA can be conferred from the mother 
during and/or shortly after the pregnancy since the immune systems of mother and 
child are in close contact and cell trafficking will occur (44-47). The phenomenon of 
NIMA was described for the first time in 1954 for the RhD antigen (48) and is 
illustrated in Figure 3. The terminology is oriented from the point of view of the child 
in a family, since most studies are coming from the transplantation field. It has been 
described that haplo-identical NIMA-mismatched sibling transplants have a graft 
survival similar to that of HLA-identical siblings in contrast to NIPA-mismatched 
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The phenomenon of protection against RA by “DERAA”-containing HLA-DRB1 
alleles as NIMA is studied in Chapter 2 of this thesis and discussed in comparison 
with the inherited effect in Chapter 3. 
 
Next to HLA-DRB1 there are several other genes involved in the risk for RA 
development. Below, only the additional risk alleles studied in the context of this thesis 
are discussed. 
PTPN22 
The protein Tyrosine phosphatase named Lyp is encoded by the protein Tyrosine 
phosphatase, non-receptor type 22 (PTPN22) gene and is expressed by many cell types 
present in haematopoietic tissues, like T cells, B cells, NK cells, monocytes, dendritic 
cells and neutrophils (52). 
Genes can differ in their nucleotide sequence between different individuals in a 
population. When the frequency of a single nucleotide change is equal or higher than 
1%, this is called a single nucleotide polymorphism (SNP). The most studied SNP of 
the PTPN22 gene, the C1858T missense single-nucleotide polymorphism, is associated 
with RA, UA (52-56) and several other autoimmune diseases (57-59). Upto now, it 
seems that the SNP does not have an effect on the severity of RA, only on the 
susceptibility (53;60). 
 There is a large variation in allele frequency among different ethnic populations 
among the world of the T-variant of the allele, with a variation only in Europe from 2-
Figure 3. Terminology of non-inherited maternal antigen (NIMA) and non-inherited 
paternal antigen (NIPA). The terminology is orientated from the point of view of the 
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3% in Italians to 15% in Finnish people (61). There are several articles describing the 
association of the PTPN22 T allele of the C1858T polymorphism with the development 
of ACPA+ RA, therefore implicating a correlation of this SNP with the production of 
ACPA (62-64). 
We investigated in Chapter 5 whether the C1858T polymorphism of the PTPN22 gene 
can give additive value to the prediction of progression from UA to RA when it is 
combined with presence of ACPA. 
Genome wide association studies (GWAS) 
In the past few years several genome wide association studies (GWAS) have been 
performed to scan the entire genome for common polymorphisms associating with 
different autoimmune diseases, including RA (65-68). Since thousands of patients and 
controls from different populations are studied in the GWAS, these studies may 
identify risk factors with modest effects on the risk for RA development, and also 
allow one to study subpopulations of patients for specific effects. 
From all genes identified to be associated with RA, we studied based on a recent 
GWAS (67) six newly identified SNPs for their influence on the severity of RA 
(Chapter 6). These SNPs are located around genes that are either involved in 
activation of the immune response (CD40, TNFRSF14, CCL21 and PRKCQ) or play a 
role in intracellular processes involving cell cycle and homeostatis (MMEL1, KIF5A 
and CDK6).  
 
Statistical modelling 
Several statistical models may be applied to the analysis of genetic associations. The 
kind of statistical model appropriate for the analysis is dependent on the correlation 
between the variables and measurement groups, the distribution of the data and the 
type of study performed. Below, two models are discussed that are used for the 
different genetic association chapters described in this thesis. 
Theory of Bayes 
To study the effect of numerous factors on the development of a disease, modelling of 
the risk factors studied is performed to fit the observed data with the expected 
frequencies. Modelling of all these risk factors preferably results in prediction of the 
outcome. A theory that calculates the probability that a hypothesis is true based on the 
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Chapter 2 and 5 of this thesis. With this theory, a prior probability (e.g. to develop 
RA), based on the risk of an individual in a certain population, is converted into a 
posterior probability, calculated on the basis of extra information derived from the risk 
factors studied. The prior probability is most often the prevalence of e.g. a certain 
disease (or symptom) in the population (69-71). 
Linear Mixed Model 
A mixed model is a multiple variance analysis often used to compare groups of 
individuals including multiple measurements from one individual e.g. in time. The data 
of every individual are plotted in a linear way, and combined for the whole group, 
thereby intrapolating missing values (72). In a mixed model both random and fixed 
effects are included. Fixed effects are categorical variables from which all levels are 
fixed and known, whereas random effects are variables where only a random sample of 
possible values is measured. A Gaussian distribution is assumed for the variables 
studied. Since all individual measurements are taken into account in one analysis, it is a 
powerful method with low intra-individual variability and therefore smaller group sizes 
are required (73). A linear mixed model was used in Chapter 6 of this thesis to study 
the effect of different SNPs on the severity of RA. 
 
Outline of the thesis 
Chapter 2 reports a family study in which we studied whether “DERAA”-containing 
HLA-DRB1 alleles protect against the development of rheumatoid arthritis not only 
when the alleles are inherited but also when they are present as a non-inherited 
maternal antigen (NIMA). 
 
Chapter 3 is a review that summarizes the epidemiological findings about “DERAA”-
containing HLA-DRB1 alleles and RA and the observation we made in Chapter 2. 
Both associations are compared and possible explanations for the protective 
phenomenon are described. 
 
On the same location in the HLA-DRB1 molecule as the “DERAA” epitope, the so-
called shared epitope (SE) can be present. These SE-containing HLA-DRB1 alleles 
predispose to the formation of ACPA and therefore the development of RA. Since 
ACPA-producing B cells are helped by T cells, we studied in Chapter 4 whether we 
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could identify possible T cell epitopes from an important ACPA target antigen, namely 
the citrullinated vimentin protein. 
Both for ACPA and the C1858T polymorphism of the PTPN22 gene associations with 
RA development have been described. We studied the individual contribution of 
ACPA and a PTPN22 SNP on the prediction of RA development from UA in Chapter 
5. We also studied the influence of the PTPN22 SNP on the level of ACPA. 
 
Genes can be involved both in the susceptibility and severity of RA. This is the case 
e.g. for the SE-containing HLA-DRB1 alleles. Therefore, we studied in Chapter 6 the 
contribution of several SNPs that were newly identified as risk factors for the 
development of RA and the severity of the disease. 
 
The results obtained in the chapters 2-6 of this thesis are summarized and discussed in 
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Abstract 
  
Rheumatoid arthritis (RA) is a complex genetic disorder in which the HLA-region 
contributes most to the genetic risk. HLA-DRB1-molecules containing the amino-acid 
sequence “DERAA” (i.e. HLA-DRB1*0103, *0402, *1102, *1103, *1301, *1302 and 
*1304) are associated with protection from RA. It has been proposed that not only 
inherited but also non-inherited HLA-antigens from the mother (NIMA) can influence 
RA-susceptibility. Up to now, no protective NIMAs were described. Here, we studied 
whether “DERAA”-containing HLA-DRB1-alleles as NIMA are associated with a 
protective effect. 
Hundred-seventy-nine families were studied, 88 from the Netherlands and 91 from the 
UK. The frequency of “DERAA”-containing HLA-DRB1-alleles of the Dutch mothers 
(16.1%), but not of the fathers (26.2%), was lower compared to the general Dutch 
population (29.3%; p=0.02). This was replicated in the English set of patients and 
controls (p=0.01). Further, of all families, 45 contained at least one “DERAA”-
negative child with RA and at least one “DERAA”-positive parent. The odds for the 
“DERAA”-negative RA patients of having a “DERAA”-positive mother was 
significantly lower as compared to having a “DERAA”-positive father (OR 0.25; 
p=0.003). 
These data show a protective NIMA-effect in a human autoimmune disease and 








Protective effect of non-inherited maternal HLA-DR antigens on RA 27 
Introduction 
 Rheumatoid arthritis (RA) is a complex genetic disorder in which the HLA-region 
contributes most to the genetic risk. Especially HLA-DRB1 molecules sharing a 
common epitope, R(Q)K(R)RAA,(i.e. the amino acids Arginine, (Glutamine), Lysine, 
(Arginine), Arginine, Alanine, Alanine) at position 70-74, the so-called shared epitope 
(SE), are associated with both susceptibility to and severity of RA (1-4). At the same 
position of the HLA-DRB1 molecules as the SE, the amino acids “DERAA” (i.e. the 
amino acids Aspartic acid, Glutamic acid, Arginine, Alanine, Alanine) can be present. 
Individuals carrying HLA-DRB1 alleles that express this “DERAA”-sequence 
(“DERAA”-positive individuals) (“DERAA” is present in HLA-DRB1*0103, *0402, 
*1102, *1103, *1301, *1302 and *1304) have a lower susceptibility to develop RA and 
less severe disease compared to individuals with ‘neutral’ (SE- and “DERAA”-
negative) HLA-DRB1 alleles. “DERAA”-containing HLA-DRB1 alleles protect in 
both SE-negative and SE-positive individuals and therefore this effect is independent 
of the effect of SE-alleles (5). 
 
It has been proposed that not only inherited but also non-inherited HLA-antigens from 
the mother (NIMA) as opposed to those from the father (NIPA) can influence the 
immune reactivity of an individual with implications for tissue transplant survival and 
susceptibility to autoimmune disease (6-8). During pregnancy the immune systems of 
mother and child are in close contact and trafficking of cells, antibodies and/or antigens 
can occur. Confrontation of the fetal/newborn immune system with the NIMA may 
have a lifelong influence on the immune response of the child. It has been shown in 
transplantation studies, that haplo-identical NIMA-mismatched sibling transplants had 
a graft survival similar to that of HLA-identical siblings, whereas NIPA-mismatched 
sibling transplants did as poorly as did recipients of maternal and paternal grafts (9). 
We have described that HLA-DR4 or SE NIMA but not HLA-DR4 or SE NIPA are 
associated with susceptibility to RA, because HLA-DR4 or SE-negative RA patients 
have more often a HLA-DR4 or SE-positive mother compared to a HLA-DR4 or SE-
positive father (10, 11). This observation was confirmed in one study (8) while in two 
other studies there was a non-significant trend in the same direction (12, 13). When the 
studies were combined a significant HLA-DR4 and SE NIMA effect in DR4 or SE 
negative patients was observed (8). This is not or less clearly the case for HLA-DR4 or 
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diabetes, HLA-DR3-DQ2 and HLA-DR4-DQ8, are also more frequent in mothers as 
compared to fathers of patients negative for one or both of these antigens (7).  
As there is so far no evidence for a protective effect in human autoimmune disease for 
NIMA we were interested to study whether “DERAA”-containing HLA-DRB1 alleles 
as NIMA are associated with a protection against RA. 
To answer this question, 88 Dutch and 91 English families were typed for HLA-DRB1. 
Families in which the RA patient did not carry a HLA-DRB1 allele containing 
“DERAA” and either the father, the mother or both carried “DERAA”-containing 
HLA-DRB1 alleles, were analyzed for the presence of a NIMA effect mediated by 
“DERAA”-containing HLA-DRB1 loci. 
 
Patients and Methods 
Dutch RA families: 88 consecutive patients with RA fulfilling the 1987 ACR criteria 
were recruited in 1996 in two outpatient clinics: 37 from the Leiden University 
Medical Centre, Leiden, and 51 from the Jan van Breemen institute, Amsterdam. At 
time of inclusion, both parents of the patient had to be alive. Blood samples were 
drawn from patients and their parents to perform HLA-DRB1 typing. 
 
Dutch Controls: A randomly selected panel of 423 healthy unrelated Dutch indivi-
duals served as control population for the Dutch HLA-DRB1 allele frequencies (5). 
 
Dutch control families: HLA-DRB1 typings of 208 healthy mothers and child pairs 
were analyzed to control for the specificity of a possible NIMA effect of “DERAA”-
containing HLA-DRB1 alleles in the RA families. These families were collected from 
a database (36) that includes deliveries that took place in of the Obstetric Department 
of the Leiden University Medical Centre. 
 
English families: Potential multi-case RA families were notified from a number of 
sources including consultant rheumatologists, routine questioning of patients in clinics 
and direct approaches via the media. Especially families with sibling pairs or extended 
affected pedigrees were identified (37). The diagnosis was confirmed by a trained 
rheumatologist. Diagnostic classification was based on the modified 1987 ARA 
Criteria (38). Blood samples of all individuals were taken for HLA-DRB1 typing. For 
the NIMA analysis, all “DERAA”-negative children with RA of each family were 
taken into account. 
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English controls: An English Caucasian study population from the Allele Frequency 
Database consisting of 177 individuals was used as control population for the English 
HLA-DRB1 allele frequencies (39). 
HLA genotyping 
HLA-DRB1 alleles were determined in all RA patients, their parents, brothers, sisters 
and controls. In the English families, seven typings of the HLA-DRB1 alleles of either 
the mother or the father were deduced from the alleles present in the other family 
members. 
 HLA-DRB1 typing for the Dutch individuals was performed as described previously 
(11). In England HLA-DRB1 typing was performed by polymerase chain reaction, 
using specific primers and hybridization with sequence-specific biotin labeled 
oligonucleotides (Dynal kit, Dynal Biotech, Wirral, UK). In four of the 88 fathers and 
one of the 88 mothers no definitive HLA-DRB1 allele could be assigned. Therefore, 
these individuals were excluded from the analysis. 
The following HLA-DRB1 alleles were classified as containing the “DERAA” epitope: 
HLA-DRB1*0103, *0402, *1102, *1103, *1301, *1302 and *1304. 
Statistics 
The patient characteristics of the Dutch and English patients were compared with either 
a Chi-square (dichotomous variables) or independent T-test (continuous variables). For 
the patient groups of table 3 (<30 individuals per group), the patient characteristics 
were compared with the Fischer exact and Mann-Whitney tests. 
The “DERAA” frequencies of the mothers and the fathers of both the Dutch and 
English RA patients were compared separately to the “DERAA” frequency in the 
Dutch and English healthy control populations, respectively, by using a Chi-square 
test. In the Dutch healthy control population, the frequency of “DERAA”-containing 
HLA-DRB1 alleles in women and men was also compared. 
An association between the presence and absence of the “DERAA”-containing HLA-
DRB1 alleles as a NIMA or a NIPA was calculated using odds ratios with 95% 
confidence intervals combined with a Chi-square test. The observed frequency of 
“DERAA”-positive mothers was compared to the expected frequency using a binomial 
test. The expected frequency was calculated with the method of Bayes and a 
comparable distribution of the English and Dutch families contributing to this analysis 
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were performed for parents of patients not carrying a “DERAA”-containing HLA-
DRB1 allele. 
The Chi-square, independent T-tests and the Binomial test were performed using 
SPSS_12.0 Software (Chicago, IL, USA). The odds ratios and 95% confidence inter-




Two different data sets were studied: Dutch RA patients with their parents and English 
RA patients with their brothers, sisters and parents. The characteristics of both data sets 
at the time of taking the blood sample for HLA-DRB1 typing are listed in Table 1.  
 
Table 1.  Clinical and laboratory characteristics of the Dutch and English patients used for 
this study. 
 Dutch English 
 (n=88) (n=223*) 
Age at onset (years) 30 32 
Disease duration (years) 7.8 11.5 
female sex (%) 86.5 79.8 
Rheumatoid Factor positive (%) 57 84 
SE positive (%) 74 86 
Erosive disease (%) 87 84 
The age at onset and disease duration show the mean values in years. Disease duration is 
the duration of rheumatoid arthritis at the time of taking the sample for HLA-DRB1 typing. 
The positivity of rheumatoid factor was also determined at the time of taking the blood 
sample for HLA-DRB1 typing. *out of 91 (multi-case) families. 
 
Both patient populations had a comparable age of onset, sex distribution and a similar 
percentage of patients with joint erosions. The young age at onset is probably due to 
the selection of patients with living parents. The English patients were more often 
rheumatoid factor (RF) and SE positive and had a longer disease duration at the time 
the blood sample for HLA-DRB1 typing was taken. These differences are most 
probably the consequence of including multi-case families in the English data set and 
mainly single case families (only 1 multi-case family) in the Dutch data set. Patients of 
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multi-case families more often are carriers of predisposing HLA-DRB1 alleles (the SE- 
alleles), often have more severe disease and therefore have a higher frequency of 
rheumatoid factor antibodies (15). Since these differences were as expected and were 
not considered  to  interfere with our research question, the  patients from both data sets 
were pooled for some analyses. 
 
The frequency of “DERAA”-containing HLA-DRB1 alleles present in the Dutch RA 
patients (“DERAA”-positive RA patients) (14.6%) was significantly lower than that of 
the Dutch healthy control population (29.3%; p=0.007). A similar observation was 
made in the English patients (only the oldest RA child of every family was included) as 
the frequency of “DERAA”-containing HLA-DRB1 alleles (8.6%) was significantly 
lower than that of the English control population (23.8%; p=0.002). These data confirm 
the protective effect associated with “DERAA”-containing HLA-DRB1 alleles. Before 
studying a possible effect of “DERAA”-containing HLA-DRB1 alleles as NIMA, we 
studied whether there was no difference in inheritance of “DERAA”-containing HLA-
DRB1 alleles from fathers or mothers to their children. Therefore, we analyzed the 
frequency of fathers and mothers that have passed on a “DERAA”-containing HLA-
DRB1 allele to “DERAA”-positive RA patients. As expected, “DERAA”-containing 
HLA-DRB1 alleles were equally inherited from fathers or mothers in both the Dutch 
and English families (data not shown). These data indicate that there is no gender 
difference in inheritance of “DERAA”-containing HLA-DRB1 alleles. 
 
If non-inherited “DERAA”-containing HLA-DRB1 alleles of the mother protect the 
child to RA development, it is expected that the frequency of mothers of RA patients 
bearing a “DERAA”-containing HLA-DRB1 allele is lower compared to the general 
population. Therefore, we determined whether the frequency of “DERAA”-containing 
HLA-DRB1 alleles of mothers and fathers of RA patients was different as compared to 
controls. The frequencies of “DERAA”-containing HLA-DRB1 alleles of the mothers 
and fathers of the 88 Dutch RA families were therefore compared with the frequency of 
“DERAA”-containing HLA-DRB1 alleles of a Dutch healthy control population (Table 
2). Twenty-two Dutch fathers (26.2%) carried a “DERAA”-containing HLA-DRB1 
allele whereas in only 14 mothers (16.1%) a “DERAA”-containing HLA-allele was 
present. When these frequencies were compared to the frequency of “DERAA”-
containing HLA-DRB1 alleles in a Dutch healthy control population (29.3 %), the 
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population. In contrast, the frequencies of the fathers of the RA patients and the 
individuals of the healthy control group were comparable.  
 
Table 2  “DERAA” frequency of mothers and fathers of Dutch and English RA patients 
compared with healthy Dutch and English controls. 
  “DERAA”+ “DERAA”- frequency OR (95% CI) p-value 
  n = n = (%)    
Dutch             
 Mothers of RA patients 14 73 16.1 0.46 (0.24-0.88) 0.02* 
 Fathers of RA patients 22 62 26.2 0.86 (0.49-1.50) 0.66 
 Contr. Fam. Mothers 67 141 32.2 1.15 (0.79-1.67) 0.51 
 Healthy controls 124 299 29.3      
            
English           
 Mothers of RA patients 9 82 9.9 0.35 (0.15-0.80) 0.01* 
 Fathers of RA patients 14 75 15.7 0.60 (0.29-1.22) 0.18 
 Healthy controls 42 135 23.8       
“DERAA”+: carriership of one or two “DERAA” containing HLA-DRB1 alleles. 
“DERAA”-: no “DERAA”- containing HLA-DRB1 allele present. Contr. Fam. Mothers: 
Mothers of the control population from the Department of Obstetrics of the Leiden 
University Medical Centre. OR= odds ratio compared to healthy controls. 95% CI= 95% 
confidence interval. 
 
These findings were replicated in the English multi-case families from Manchester. In 
these English RA families 9 mothers out of a total of 91 (9.9%) carried a “DERAA”-
containing HLA-DRB1 allele, compared to 14 fathers (15.7%). When these frequencies 
were compared to the frequency of “DERAA”-containing HLA-DRB1 alleles in the 
population of English Caucasians (23.8%), the frequency of “DERAA”-containing 
HLA-DRB1 alleles of the mothers was significantly reduced (p=0.01) in contrast to the 
frequency of “DERAA”-containing HLA-DRB1 alleles of the fathers (p=0.18). The 
fact that the “DERAA” frequency of the fathers was also (non-significantly) lower that 
that of the controls is probably due to the fact that the English families were multi-case 
families which are expected to have a lower frequency of the protective “DERAA”-
containing DRB1 alleles. 
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To exclude the possibility that the difference in “DERAA”-containing HLA-DRB1 
allele frequency between the mothers and fathers is due to a general difference in 
“DERAA”-containing HLA-DRB1 allele frequency between males and females, the 
frequencies of “DERAA”-containing HLA-DRB1 alleles in males and females of the 
Dutch healthy control cohort were analyzed. Fifty out of 186 women carried one or two 
“DERAA”-containing HLA-DRB1 alleles (26.8%) compared to 67 out of 232 men 
(29.5%). These frequencies were not significantly different (OR= 0.91; 95%CI 0.58-
1.42; p=0.73), indicating that the lower frequency of “DERAA”-containing HLA-
DRB1 alleles in the mothers as compared to the fathers of RA patients points to a 
mother-specific effect of “DERAA”-containing HLA-DRB1 alleles on the child. 
To further ascertain that the observed difference in frequency of “DERAA”-containing 
HLA-DRB1 alleles between mothers and fathers of RA patients could indeed be 
attributed to an effect of non-inherited HLA-antigens, the “DERAA”-positive families 
with a “DERAA”-negative child (the RA patient) were selected for further analysis. 
The patient characteristics of this group were comparable to the data shown in Table 1 
except for a borderline significant difference in sex in the English patient group 
(p=0.04). Since the patient characteristics between the Dutch and English patients (as 
shown in Table 1) only differed for the expected characteristics (RF, SE and disease 
duration), the patients were pooled for further analysis. From the 45 families fulfilling 
the selection criterion, 17 “DERAA”-positive mothers and 32 “DERAA”-positive 
fathers were identified (Table 3).  
 
Table 3  Mothers of “DERAA”-negative RA patients carry less often a “DERAA”-
containing HLA-DRB1 allele than fathers. 
 DERAA+ DERAA- frequency OR (95% CI) p-value 
 n = n = (%)    
Mothers 17 28 37.8 0.25 (0.09-0.65) 0.003* 
Fathers 32 13 71.1      
The data of the English and Dutch families are combined. 
“DERAA”+: carriership of at least one “DERAA”-containing HLA-DRB1 allele. 
“DERAA”-: no “DERAA”- containing HLA-DRB1 allele present. The frequency is the 
percentage DERAA-positive individuals. OR= odds ratio of mothers compared to fathers. 
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The odds ratio (OR) for “DERAA”-negative RA patients of having a “DERAA”-
positive mother compared to a “DERAA”-positive father was 0.25 (95% CI 0.09-0.65; 
p=0.003). The observed frequency of “DERAA”-positive mothers (37.8%) was also 
significantly decreased compared to the expected frequency (53.6%; p=0.02). When 
the data of the 45 families were stratified for SE status of the patient (i.e. either no SE 
alleles or heterozygous or homozygous for SE) no significant differences were 
observed between the OR of the DERAA-NIMA versus -NIPA between the different 
subgroups (data not shown), indicating that the observed NIMA effect of DERAA-
containing HLA-DRB1 alleles is probably independent of SE status. However the 
numbers in the different subgroups were small, particularly for the SE negative 
patients. 
Finally to exclude that also in non-RA families there is a NIMA effect of “DERAA”-
containing HLA-DRB1 alleles, a Dutch control population (mother-child pairs from the 
LUMC Department of Obstetrics) was analyzed. The frequency of “DERAA”-
containing HLA-DRB1 alleles in both the mothers (32.2%, Table 2) and children 
(30.3%) were comparable with that of the Dutch healthy control population (29.3%), 
showing that there is no (NIMA) effect of “DERAA”- containing HLA-DRB1 alleles 
in healthy control families. These results together show that there is a protective effect 




It has been proposed that not only inherited but also non-inherited HLA-antigens from 
the mother (NIMA) as opposed to those from the father (NIPA) can influence the 
immune reactivity of an individual. A beneficial NIMA effect has been demonstrated 
in organ and bone marrow transplantations (6, 9, 16) and a susceptibility-effect of HLA 
class II molecules as NIMA were shown to be associated with susceptibility to 
rheumatoid arthritis and diabetes (7, 10, 11). Although it has been shown that diabetes 
is transmitted less frequently to the offspring of diabetic women than those of diabetic 
men, no relationship with HLA alleles  or other genetic variations was described (17, 
18) and therefore, direct evidence for a protective effect of HLA antigens as NIMA in 
autoimmune diseases is thus far lacking.  In this study we show that there is a 
protective effect of HLA-DRB1 molecules that contain the amino acid sequence 
“DERAA” as NIMA on the development of RA. The odds ratio (OR) for “DERAA”-
negative RA patients of having a “DERAA”-positive mother compared to a 
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“DERAA”-positive father was 0.25. These data show a protective NIMA-effect in a 
human autoimmune disease and indicate that a “DERAA”-positive mother can transfer 
protection against RA to her “DERAA”-negative child. 
 
HLA-DRB1 molecules play a large role in the genetic risk of developing RA. At 
position 70-74 of the HLA-DRB1 molecules either the amino acids of the SE 
(R(Q)K(R)RAA) can be present or the amino acids “DERAA”. The odds ratio of 
individuals carrying HLA-DRB1 alleles that express the “DERAA”-sequence (HLA-
DRB1*0103, *0402, *1102, *1103, *1301, *1302 and *1304) compared to individuals 
with “neutral” (SE- and “DERAA”-negative) HLA-DRB1 alleles to develop RA is 0.5-
0.7, indicating that “DERAA”-positive individuals have a lower susceptibility to 
develop RA (5, 19-21). Since the odds ratio of “DERAA” was corrected for SE-alleles, 
it can be concluded that the “DERAA”-containing HLA-DRB1 alleles are 
independently associated with a reduced risk to develop RA. The mechanism of 
protection is unknown, but it has been  proposed that it is mediated by T cells 
recognizing peptides containing the “DERAA”-sequence presented by HLA-DQ 
molecules (22). Whether these T cells have a regulatory phenotype or are deleted in the 
thymus by negative selection is still a subject of research. Our observation of a 
protective effect of “DERAA”-containing HLA-DRB1 alleles as NIMA on RA 
development gives a new dimension to the direction of this research. 
 
During pregnancy, cells of the mother migrate to the fetus and may induce lifelong 
microchimerism in the child (23-25). Maternal microchimerism has been shown in 
mice to induce neonatal B cell (26) and probably also T cell (27) tolerance and is 
therefore one of the possible mechanisms for NIMA effects (28). Although speculative, 
we postulate therefore that the protective effect of the DERAA-containing HLA-DRB1 
alleles as NIMA on the development of RA is most probably mediated by maternal 
cells entering the bloodstream and tissues of the child which exert their effect through a 
change in the immune repertoire and most likely the T cell repertoire of the child. 
These maternal cells might influence thymic selection or act in the peripheral lymphoid 
organs, for example as a consequence of the sustained presence of cells from the 
mother in the child. It has been shown that maternal microchimeric cells can be present 
in many different cell subsets (29) in both healthy and diseased individuals (30, 31) in 
which they may exert different effects (32, 33). Likewise, immune regulatory 
mechanisms might directly be induced in the fetus as it has recently been described that 
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in utero (34) or becomes sensitized against foreign antigens to which the mother is 
exposed during pregnancy (35).  
Further studies on the intriguing interplay between the developing immune system of 
the child and cells from the mother are needed both to increase our understanding on 
how NIMA can influence the immune system of the child and to learn whether and if 
so how this might be used to combat autoimmune diseases. 
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Abstract 
  
The human HLA-region contributes most to the genetic risk for Rheumatoid arthritis 
(RA), either in a predisposing- or a protective fashion. HLA-DRB1-molecules 
containing the amino-acid sequence “DERAA” at position 70-74 of the DRbeta chain 
are less often present in RA-patients compared to controls. It has been proposed that 
antigens transmitted from the mother, but not genetically inherited (called NIMA), can 
influence RA-susceptibility. Confrontation of the fetal/newborn immune system with 
the NIMA is supposed to have a lifelong modulating impact on the immune response 
of the child and thus on the chance to develop RA. Up to now, no protective NIMAs 
were described in autoimmunity. Recently, we studied whether “DERAA”-containing 
HLA-DRB1-alleles as NIMA are associated with a protective effect. We showed a 
protective NIMA-effect in RA as “DERAA”-positive mothers -in contrast to 
“DERAA”-positive fathers- could transfer protection to their “DERAA”-negative 








Protection against RA by HLA:Nature and Nurture 41 
Summary 
Rheumatoid arthritis (RA) is a complex genetic disorder in which the HLA-region 
contributes most to the genetic risk. HLA-DRB1-molecules containing the amino-acid 
sequence QKRAA/QRRAA/RRRAA (i.e. HLA-DRB1*0101, *0102, *0401, *0404, 
*0405, *0408, *0410, *1001 and *1402) at position 70 to 74 in the third hypervariable 
region of the DRB1 chain are associated with susceptibility to RA. HLA-DRB1 
molecules containing the amino acids “DERAA” (i.e. HLA-DRB1*0103, *0402, 
*1102, *1103, *1301, *1302 and *1304) at the same position are associated with 
protection from RA. 
Interestingly, not only inherited but also non-inherited HLA-antigens from the mother 
can influence RA-susceptibility. We have recently described a protective effect of 
“DERAA”-containing HLA-DRB1 alleles as non-inherited maternal antigen (NIMA). 
The underlying mechanism of this protective effect is currently unknown, although a 
possible explanation is covered below. In this review, an overview of the current 
knowledge on protection against RA is given and the inherited and NIMA effect of 
“DERAA”-containing HLA-DRB1 alleles are compared. 
 
HLA-DRB1 "DERAA"-positive alleles protect against RA 
Rheumatoid arthritis (RA) is a complex genetic disorder in which the HLA-region 
contributes most to the genetic risk. Especially HLA-DRB1 molecules sharing a 
common epitope, R(Q)K(R)RAA, (i.e. the amino acids Arginine, (Glutamine), Lysine, 
(Arginine), Arginine, Alanine, Alanine) at position 70-74 in the third hypervariable 
region of the DRB1 chain, the so-called shared epitope (SE), are associated with both 
susceptibility to and severity of RA (1-4). The shared epitope is present in the HLA-
DRB1*0101, *0102, *0401, *0404, *0405, *0408, *0410, *1001 and *1402 molecules. 
At the same position as the SE, the amino acids “DERAA” (i.e. the amino acids 
Aspartic acid, Glutamic acid, Arginine, Alanine, Alanine) can be present in other HLA-
DRB1 molecules (i.e. HLA-DRB1*0103, *0402, *1102, *1103, *1301, *1302 and 
*1304). Individuals carrying HLA-DRB1 alleles that express this “DERAA”-sequence  
display a lower susceptibility to develop RA and suffer from less severe disease as 
compared to individuals with ‘neutral’ (SE- and “DERAA”-negative) HLA-DRB1 
alleles. The odds ratio of individuals carrying HLA-DRB1 alleles that express the 
“DERAA”-sequence compared to individuals with “neutral” (SE- and “DERAA”-
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positive individuals have a lower susceptibility to develop RA (5-8). The protective 
effect associated with “DERAA” is also found after stratification for the presence or 
absence of HLA-SE alleles. This indicates that the protective effect associated with 
“DERAA”-expression cannot be explained by an overrepresenation of SE alleles in 
patients, resulting automatically in a lower frequency of other HLA alleles in RA 
patients. Thus, the “DERAA”-containing HLA-DRB1 alleles are independently 
associated with a reduced risk to develop RA (5). 
It is unclear whether the entire “DERAA” motif is essential for the protection or that 
only certain amino acids of this motif confer the same effect. In contrast to several 
reports showing the protective effects by “DERAA”-containing HLA-DRB1 alleles to 
the development and severity of RA (5,9,10), other reports hypothesize that the amino 
acids “RAA” at position 72-74 in the third hypervariable region influence the 
susceptibility to RA development whereas the amino acids at position 70 and 71 
modulate this effect (11,12). In these articles it is indicated that HLA alleles expressing 
the 70ERAA74 sequence or the Aspartic acid (D) at position 70 both have a lower 
frequency in RA patients as compared to healthy controls. Further, it has also been 
described that protection is mainly associated with the Aspartic acid (D) at position 70 
(8,13). 
Thus, despite these differences in nomenclature and stratification, it is getting 
increasingly clear that some HLA alleles confer susceptibility, whereas others are 
associated with protection. 
The mechanism of protection is unknown, but it has been proposed that it is mediated 
by T cells recognizing peptides containing the “DERAA”-sequence presented by HLA-
DQ molecules (14). Whether these T cells have a regulatory phenotype or are deleted 
in the thymus by negative selection is still a subject of research. 
 
Non-inherited "DERAA" from the mother also  
gives protection to the child for RA development 
In 1954 Owen et al. described that Rhesus D ( RhD) negative children  were tolerant to 
the RhD antigen when they had a RhD positive mother, probably due to exposure to 
the RhD antigens during pregnancy (15). This was the first time that a biological effect 
of non-inherited maternal antigen (NIMA) was described. This terminology is 
exemplified in Figure 1.  Confrontation of the fetal/newborn immune system with the 
NIMA may have a lifelong influence on the immune response of the child. This 
phenomenon has considerable implications for transplantation and most studies on 
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NIMA are coming from the transplantation field. Claas et al. described that renal 
transplant patients often do not generate antibodies against the mismatched HLA 
antigens of their mother in comparison to those of their father and are therefore tolerant 
for this HLA mismatch when they are transplanted. This is associated with a longer 
transplant survival (16-18). This is exemplified best in a study by Burlingham showing 
that haplo-identical NIMA-mismatched sibling transplants have a graft survival similar 
to that of HLA-identical siblings, whereas NIPA-mismatched sibling transplants did as 
poorly as did recipients of maternal and paternal grafts (19). 
 
 
We have recently shown that there is also a protective effect on the development of RA 
of HLA-DRB1 molecules that contain the amino acid sequence “DERAA” when 
presented as NIMA on the development of RA (20). We anticipated that if non-
inherited “DERAA”-containing HLA-DRB1 alleles of the mother protect the child to 
RA development, it is expected that the frequency of mothers of RA patients bearing a 
“DERAA”-containing HLA-DRB1 allele is lower compared to the general population. 
Indeed, using a cohort of Dutch RA patients together with their parents, we were able 
to show that the mothers of RA patients showed a significantly lower frequency 
(16.1%) of “DERAA”-containing HLA-DRB1 alleles compared to the Dutch control 
population (29.3%; p = 0.02). In contrast, the frequencies of “DERAA”-containing 
HLA-DRB1 alleles in the fathers of the RA patients (26.2%) and the individuals of the 
healthy control group were comparable. These findings were replicated in the English 
Figure 1.  Terminology of non-inherited maternal antigen (NIMA) and non-inherited 
paternal antigen (NIPA). The terminology is orientated from the point of view of the 
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multi-case families from Manchester. To further ascertain that the observed difference 
in frequency of “DERAA”-containing HLA-DRB1 alleles between mothers and fathers 
of RA patients could indeed be attributed to an effect of non-inherited HLA-antigens, 
the “DERAA”-positive families with a “DERAA”-negative child (the RA patient) were 
selected for further analysis. For this analysis, the patients from the UK and the 
Netherlands were pooled. The odds ratio (OR) for “DERAA”-negative RA patients of 
having a “DERAA”-positive mother compared to a “DERAA”-positive father was 0.25 
(95% CI 0.09-0.65; p=0.003). These results together show that there is a protective 
effect of “DERAA”-containing HLA-DRB1 alleles as NIMA on development of RA of 
the child. 
 







(n = 89) 
Controls 
(n = 206) 
A pos pos 7 39 
B neg pos 6 23 
C pos neg 8 26 
D neg neg 68 118 
The Dutch families were used for this analysis [20]. Group B vs D is the inherited effect. 
OR = 0.45 (0.16-1.25); Group C vs D reflects the NIMA effect. OR = 0.53 (0.21-1.31).  
Pos = positive (hetero-zygote)  for “DERAA”-containing HLA-DRB1 alleles. Neg = 
negative for “DERAA”-containing HLA-DRB1 alleles. 
 
Thus, together these data indicate that both “DERAA”-containing HLA-DRB1 alleles 
inherited from one of the parents and the presence of “DERAA” containing HLA-
DRB1 alleles as a NIMA protect against the development of rheumatoid arthritis. The 
question that arises from these observations is how the strengths of both effects 
compare to each other. To answer this question, both effects were compared in the 
same set of patient and control families. Only Dutch families (20) were included in this 
analysis for a proper comparison to the control families. The data depicted in table 1 
indicate that, indeed, the effect of “DERAA”-containing HLA-DRB1 alleles as NIMA 
is as strong as the effect observed in case the “DERAA”-alleles are inherited directly 
from one of the parents. Although not significant (over 7000 families would be 
required to discriminate whether the inherited and non-inherited protection differ 
significantly or not), these data indicate that both effects are of the same magnitude. 
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The comparable effect size described here is similar as the observations made in the 
transplantation setting (19). 
 
This result would be in line with the assumption that only very few cells can exert the 
protective effect. One of the few cell populations that can give rise to many different 
cell types and has a life long existence are the stem cells. During pregnancy the 
immune systems of mother and child are in close contact and trafficking of cells, 
antibodies and/or antigens can occur. Therefore the most plausible explanation for the 
observed NIMA effect of “DERAA”-containing HLA-DRB1 molecules is maternal 
microchimerism.  
Moreover, because the NIMA effect is not taken into account in most studies analyzing 
the contribution of the HLA system to RA susceptibility, these data also indicate that 
the association would be even more prominent in case an effect of  “DERAA” as 
NIMA would have been considered. 
 
Microchimerism as a possible mechanism of the 
NIMA-effect 
During pregnancy there is a bidirectional maternal-fetal lymphocytic transfer (21). 
Occurrence of these cells starts after about three months of gestation and persists till 
delivery (22). It is shown that the levels of fetal DNA in the circulation of the mother 
increase during these six months and disappear for the largest part after delivery (23). 
During pregnancy also cells of the mother migrate to the fetus and may induce lifelong 
microchimerism in the child (21,24,25). Maternal microchimerism has been shown in 
mice to induce neonatal B cell (26) and probably also T cell (27) tolerance and is 
therefore one of the possible mechanisms for NIMA effects (28) Although speculative, 
we postulate therefore that the protective effect of the DERAA-containing HLA-DRB1 
alleles as NIMA on the development of RA is most probably mediated by maternal 
cells entering the bloodstream and tissues of the child which exert their effect through a 
change in the immune repertoire and most likely the T cell repertoire of the child. 
These maternal cells might influence thymic selection or act in the peripheral lymphoid 
organs, for example as a consequence of the sustained presence of cells from the 
mother in the child. It has been shown that maternal microchimeric cells can be present 
in many different cell subsets (29) in both healthy and diseased individuals (30,31) in 
which they may exert different effects (32,33). Likewise, immune regulatory 
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the fetus can already develop cytotoxic T cells directed at a maternal minor H antigen 
in utero (34) or becomes sensitized against foreign antigens to which the mother is 
exposed during pregnancy (35). Although the presence of maternal microchimerism is 
not rare, there are several reports that the amount of microchimerism influences the 
sensitivity of an individual to certain diseases (30,31,36,37). 
The observation that the inherited and NIMA effect of “DERAA” have approximately 
similar effect size strengthens the idea that the NIMA effect is caused by lifelong 
circulating microchimeric cells that play a role in the thymic selection and therefore 
influence the T cell repertoire. Only when the inherited and the NIMA acquired 
“DERAA” have the same mechanism of induction of protection, the similar strength 
can be explained. 
 
Overall, we can conclude from the data presented in this review that the presence of 
“DERAA”-containing HLA-DRB1 molecules can protect an individual against the 
development of rheumatoid arthritis. The “DERAA”-containing HLA-DRB1 
molecules can either be present since the individual has inherited them directly or 
because the individual had a “DERAA”-positive mother and acquired some of the 
“DERAA”-containing HLA-DRB1 molecules during fetal and/or neonatal life. The 
protective effect that is acquired in either way is of similar strength, which suggests 
that already a low amount of cells can initiate this protective effect. Further research is 
required to elucidate the mechanism of protection of both the inherited as the NIMA 
effect of the “DERAA”-containing HLA-DRB1 molecules. Such research might be 
very rewarding as it could guide the way to the development of novel therapies 
initiating protection in a similar manner as provided by “DERAA”-positive mothers to 
their “DERAA”-negative children.  
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Abstract 
  
Objective. Antibodies directed against citrullinated proteins (ACPA) are highly 
specific for rheumatoid arthritis (RA). The production of ACPA is most likely 
dependent on the presence of T cells as ACPA have undergone isotype-switching and 
associate with the shared epitope-containing HLA-DRB1 alleles (SE). Vimentin is a 
likely candidate-protein for T cell recognition since over 90% of patients harbouring 
ACPA reactive with (peptides derived from) citrullinated vimentin carry SE-containing 
HLA-DRB1 alleles. 
The aim of this study was to identify citrullinated vimentin-peptides presented to HLA-
DRB1*0401 restricted T cells. 
Methods. HLA-DR4-transgenic mice were immunized with all possible citrulline-
containing peptides derived from vimentin and T cell reactivity was analyzed. Peptides 
recognized in a “citrulline”-specific manner by T cells were selected and analyzed for 
their ability to be processed from the entire vimentin protein. A first inventory for 
recognition of selected epitopes by T cells from HLA-DR4+ ACPA+ RA patients was 
performed. 
Results. A “citrulline”-specific response was observed for two of the peptides 
analyzed. These peptides are naturally processed from the vimentin protein as 
citrullinated vimentin was recognized by peptide-specific T cells. T cell reactivity 
against these peptides was also observed in cell cultures from RA patients. 
Conclusion. We have identified for the first time two naturally processed peptides 
from vimentin that are recognized by HLA-DRB1*0401 restricted T cells in a 
“citrulline”-specific fashion. These peptides can be recognized by T cells from HLA-
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Introduction 
 Rheumatoid Arthritis (RA) is a chronic, systemic, inflammatory autoimmune disease, 
characterized by the presence of autoantibodies. Among the autoantibodies described 
in RA, antibodies directed against citrullinated proteins (ACPA) are highly specific and 
predictive for RA (1-3) and can be detected in approximately 70-80% of long-standing 
RA patients. Antigens recognized by ACPA are present in the inflamed joint (4;5). The 
production of ACPA is most likely dependent on the presence of T cells as ACPA have 
undergone isotype-switching. 
HLA class II alleles are the most important genetic risk factor for RA. Notably HLA-
DRB1 molecules sharing a common epitope, R(Q)K(R)RAA, at position 70-74 in the 
third hypervariable region of the DRB1 chain, the so-called shared epitope (SE), are 
associated with both susceptibility to and severity of RA (6-9). It has been shown that 
the SE-containing HLA-DRB1 alleles predispose to ACPA+ disease, but not to ACPA- 
RA (10), and that they are associated with the production of ACPA (11). The latter 
provides an additional indication for the existence of T cell responses underlying the 
production of ACPA. 
Several human proteins were found to be citrullinated in vivo, one of which is 
vimentin, also known as the Sa-antigen (12-15). Citrullinated vimentin has been shown 
to be present in the synovial fluid of RA patients and to be recognized by ACPA in 
approximately 40% of RA patients (13;16-18). Furthermore, we have shown that over 
90% of ACPA+ RA patients recognizing a citrullinated peptide derived from human 
vimentin (19) and 80% of ACPA+ RA patients recognizing the Sa-antigen (unpublished 
data) carry at least one SE-containing HLA-DRB1 allele. These observations not only 
show that the SE-containing HLA-DRB1 alleles influence the specificity of the ACPA-
response, but also suggest that vimentin could be a protein involved in the recruitment 
of T cell help for ACPA-producing B cells. 
Here, we examined whether we could identify CD4+ T cells that are specific for 
citrullinated peptides from the human vimentin protein presented in the context of the 
most frequent SE-containing HLA-DRB1 allele, HLA-DRB1*0401. To this end, we 
used an unbiased approach by testing the capacity of all possible citrullinated peptides 
derived from human vimentin to induce T cell responses in DR4-transgenic mice. 
Epitope mapping in HLA-transgenic mice, both for class I and II, has been shown to be 
a reliable method to identify T cell epitopes that are also recognized by human T cells 
(20-24), and therefore we anticipate that the epitopes identified in HLA-transgenic 
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naturally-processed peptides of citrullinated vimentin that were recognized by HLA-
DRB1*0401 restricted T cells in a “citrulline”-specific manner. Reactivity against 
these two peptides was also observed with peripheral blood mononuclear cells (PBMC) 
of HLA-DRB1*04+ ACPA+ RA patients. 
These studies identified, for the first time, human “citrulline”-specific T cell responses 
against naturally processed epitopes from an autoantigen present in the inflamed joint. 
Therefore, they provide a rationale for more comprehensive analyses in RA patients. 
 
Material and Methods 
Mice 
DR4-Transgenic mice (HLA-DRB1*0401, -DRA1*0101, hCD4 transgenic mice) 
lacking endogenous MHC class II were kindly provided by L. Fugger (25) and bred in 
the in-house mice facility. 
Patients and Controls 
Blood was obtained from HLA-DRB1*04+ healthy donors after informed consent and 
PBMC were isolated by ficoll-paque. Patients carrying at least one HLA-DRB1*04 
allele who were positive for ACPA, were recruited from the Leiden Early Arthritis 
Clinic (EAC) (26). Patient characteristics are shown in Table 1.  
Peptides/protein 
The vimentin gene was amplified by PCR and cloned by Gateway Technology 
(Invitrogen, San Diego, CA) in a bacterial expression vector containing an N-terminal 
histidine tag. The protein was overexpressed in Escherichia coli BL21(DE3) and 
purified by immobilized metal chelate affinity chromatography on Ni-NTA beads, as 
described before (27). The protein was citrullinated in a 0.1 M Tris pH7.6 solution by 
adding PAD type II (20 U/ml) (from rabbit skeletal muscle, Sigma Aldrich) and 10 
mM CaCl2 for 3 hours at 55 ºC. 
The peptides were chemically synthesized at the peptide facility of the Leiden 
University Medical Centre (LUMC) and dissolved in PBS/0.05% DMSO. Every 
peptide was designed with a citrulline in the middle of the peptide with a total length of 
19 amino acids. In total, the vimentin protein contains 43 arginine residues, but 33 
peptides were synthesized (vim1-33, Table 2) in citrullinated form since some peptides 
contain two citrulline-residues in close proximity. Peptides able to induce a T cell 
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response in DR4-transgenic mice were also synthesized in non-citrullinated form. The 
citrullinated peptides were grouped in six pools of five peptides and one pool of three 
peptides. 
 













PBMC from 10 ACPA+ RA patients were isolated and tested for the presence of T cell 
responses against the identified citrullinated vimentin epitopes. The age (in years), gender 
and HLA-DRB1 alleles of each patient are depicted. From the patients tested for anti-Sa 
antibodies, 66% was positive. 
 
Immunization protocol and epitope mapping 
DR4-transgenic mice were injected with 100 l of the peptide pools or individual 
peptides (100 g/peptide) emulsified in complete Freunds adjuvant (CFA, Difco) 
subcutaneously in the base of the tail. On day 21, the mice were boosted with the same 
peptide pool or peptide (100 g/peptide) emulsified in incomplete Freunds adjuvant 
(IFA, Difco) subcutaneously in the flank. On day 42-49 after the first immunization, 
spleen cells were isolated and restimulated once with the immunizing antigen (10 
g/ml peptide) at a density of 4x10E6 cells per well in 24-wells plates in culture 
medium (IMDM/8%FCS/penicillin/streptomycin/0.02 mM -mercapto ethanol). Four 
days later, cells were harvested with 2mM EDTA and centrifuged on ficoll-paque 
gradient. Next, cells were rested for another 3 days at a density of 10E6 cells per well 
in the presence of 3 cU/ml rIL2. On day 7, cells were harvested and tested at the 
Patient Age gender HLA-DRB1 
1 62 female 0404 1101 
2 53 female 0301 0401 
3 75 female 0401 0408 
4 49 female 0101 0401 
5 49 male 0401 0101 
6 59 female 0401 0901 
7 68 male 0401 14 
8 38 male 0401 1404 
9 62 female 0401 10 
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Table 2.   Peptides synthesized from the vimentin protein  
nr AA sequence citrullinated peptide AA sequence non-citrullinated peptide 
1 MSTXSVSSSSYXXMFGGPG  
2 XSVSSSSYXXMFGGPGTAS  
3 MFGGPGTASXPSSSXSYVT  
4 GTASXPSSSXSYVTTSTXT  
5 SSXSYVTTSTXTYSLGSAL SSRSYVTTSTRTYSLGSAL 
6 XTYSLGSALXPSTSXSLYA  
7 GSALXPSTSXSLYASSPGG  
8 SSPGGVYATXSSAVXLXSS  
9 YATXSSAVXLXSSVPGVXL  
10 XLXSSVPGVXLLQDSVDFS  
11 AINTEFKNTXTNEKVELQE  
12 EKVELQELNDXFANYIDKV  
13 XFANYIDKVXFLEQQNKIL  
14 EQLKGQGKSXLGDLYEEEM  
15 DLYEEEMXELXXQVDQLTN  
16 VDQLTNDKAXVEVEXDNLA  
17 NDKAXVEVEXDNLAEDIMX  
18 DNLAEDIMXLXEKLQEEML  
19 EKLQEEMLQXEEAENTLQS  
20 EAENTLQSFXQDVDNASLA  
21 DNASLAXLDLEXKVESLQE  
22 KPDLTAALXDVXQQYESVA  
23 FADLSEAANXNNDALXQAK  
24 AANXNNDALXQAKQESTEY  
25 QAKQESTEYXXQVQSLTCE  
26 KGTNESLEXQMXEMEENFA  
27 AANYQDTIGXLQDEIQNMK  
28 QNMKEEMAXHLXEYQDLLN  
29 ALDIEIATYXKLLEGEESX  
30 XKLLEGEESXISLPLPNFS  
31 LPNFSSLNLXETNLDSLPL LPNFSSLNLRETNLDSLPL 
32 LPLVDTHSKXTLLIKTVET  
33 TLLIKTVETXDGQVINETS  
Every peptide number (nr) is followed by the amino acid (AA) sequence of the 
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indicated cell concentrations in round-bottom 96-wells plates. 100,000 irradiated 
spleen cells from a naive mouse and the different peptide pools/peptides (10 
g/ml/peptide) or recombinant (citrullinated) vimentin (20 g/ml) were added to each 
well. As a positive control, either 20 cU/ml rIL2 or PHA (1 g/ml) was used. Every 
condition was tested in triplo. Four days later, 3[H]-Thymidine was added to the wells 
for 16 hours. The plates were harvested in the Tom-Tec Mach3 harvester (Perkin 
Elmer, The Netherlands) and counts were measured using the 1450 Microbeta counter 
(Perkin Elmer, Groningen, The Netherlands). To determine the restriction of the T cell 
response, blocking antibodies against HLA-DR (B8.11.2) (28) were used. 
ELISA 
Supernatants from the stimulated spleen cells were removed before addition of 3[H]- 
Thymidine and IFN was measured using a standard sandwich ELISA. The rat-anti-
mouse coating- and detection antibodies were purchased from BD Pharmingen. 
Streptavidin-HRP (Sanquin) and ABTS (Sigma-Aldrich) were used as enzyme and 
substrate, respectively. Stimulation indices (SI) were calculated by dividing the amount 
of IFN produced upon antigenic stimulation by the amount produced by non-
stimulated cells. The error bars represent the standard error of the mean. 
Intracellular cytokine staining 
Peripheral blood mononuclear cells (PBMC) from healthy individuals or patients from 
the EAC cohort were isolated and 3x10E6 cells/well were cultured for 2 hours in a 24-
wells plate with the different citrullinated peptides (10 g/ml) or Memory Mix (mix of 
Candida Albicans (0.005%), Tetanus Toxoid (0.75 Lf/ml) and tuberculin purified 
protein derivative (PPD) (5 g/ml)) as a positive control. After removal of the antigen, 
the cells were cultured for 4 days in IMDM/5% pooled human serum/penicilline/ 
streptomycin. On day 4, 2x10E6 autologous PBMC were plated in 24-wells plates and 
non-adherent cells were removed after two hours of incubation. 1-2x10E6 Cultured 
cells were added to the adherent antigen presenting cells and restimulated with antigen 
overnight. For the last 14 hours of stimulation, 3 g/ml Brefeldin A (Sigma-Aldrich) 
was added to the wells. Next, cells were stained for the cell surface markers CD3, CD4 
and CD45RA (20 min, on ice) and intracellular IFN was stained using the BD 
cytofix/cytopermTM fixation/ permeabilization solution kit (BD Biosciences) according 
to the manufacturers instructions. Antibodies both for surface and intracellular markers 
were purchased from BD Biosciences. Data acquisition and analysis were performed 
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Statistics 
For the statistical analysis of the peptide and protein responses, paired T-tests were 
performed in Graphpad Prism version 4.0. p-values lower than 0.05 taking into account 
the 95% confidence interval were considered significant. 
 
Results 
Based upon several lines of evidence (12-17;19), we hypothesize that vimentin 
represents a relevant candidate autoantigen recognized by HLA-SE-restricted T cells. 
To identify vimentin epitopes recognized by T cells, we have chosen an unbiased 
approach in which all possible citrullinated peptides of human vimentin (Table 2) were 
analyzed for their ability to induce a T cell response in DR4-transgenic mice. 
Peptide Pools inducing antigen-specific T cell responses 
To enable efficient analyses of the large number of peptides generated, we made a first 
selection of potential epitopes by immunizing DR4-transgenic mice with seven peptide 
pools. “Peptide-pool”-specific T cell responses were repeatedly observed in bulk 
cultures obtained from mice immunized with peptide pool 1 and 7 (Figure 1A). No 
response was observed against these peptide pools when spleen cells from naive mice 
were tested (data not shown). These results indicate that the immunogenic citrullinated 
T cell epitopes are among the peptides contained in peptide pools 1 and 7. 
Characterization of immunogenic peptides 
Next, we wished to identify the individual peptides responsible for the induction of T 
cell responses by the respective peptide pool. Therefore, DR4-transgenic mice were 
immunized with peptide pool 1 or 7 and the T cell reactivity to the peptide pool as well 
as to the individual peptides from the pool was analyzed. A dose-dependent T cell 
response of spleen cells from mice immunized with peptide pool 1 was observed after 
stimulation with peptide 5 (vim26-44) (Figure 1B). Likewise, peptide 31 (vim415-433) 
was consistently recognized by spleen cells from mice immunized with peptide pool 7 
(Figure 1C). Together, these results indicate that the citrullinated peptides 5 and 31 are 
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Figure 2. IFNγ response of bulk spleen cell cultures from DR4-transgenic mice 
immunized with the indicated citrullinated peptides and tested against the citullinated 
(cit; black bars) and non-citrullinated (nc; grey bars) peptide.  
A. Cell titration showing the response to vim5 from one representative experiment.  
B. Overview of the responses against vim5 with 100,000 c/w.  
C. Cell titration for the response against vim31 from one representative experiment.  
D. Overview of the responses against vim31 with 50,000 c/w.  
The bars in A and C represent the mean response measured in triplicate +/- the SEM.  
In B and D each symbol represents the mean of a triplicate and one set of symbols 
connected by a line represents one independent experiment. The inlays show the 
stimulation indices (SI) against the citrullinated (black bar) and non-citrullinated (grey 
bar) peptides +/- the SEM. 
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To determine whether the response observed against these two citrullinated vimentin 
peptides is “citrulline”-specific, mice were immunized with these peptides and their 
spleen cells were restimulated in vitro with the same peptides. Subsequent proliferation 
of spleen cells against either the citrullinated or non-citrullinated form of the peptides 
was assessed. A dose-dependent T cell response was observed against citrullinated 
vim5 while no responses could be observed in response to the non-citrullinated 
counterpart (Figure 2A&B). On average, the stimulation index (SI) of the cultures 
restimulated with citrullinated vim5 was approximately six times higher compared to 
cultures stimulated with the non-citrullinated control peptide (Figure 2B, inlay). 
Similar results were obtained for vim31 (Figure 2C&D). In this case the T cell 
response was on average nine times higher upon stimulation with the citrullinated 
peptide as compared to the non-citrullinated peptide (Figure 2D, inlay). No IFN was 
detected when spleen cells from sham-immunized mice (i.e. CFA/IFA without peptide) 
restimulated with either citrullinated peptide were used (data not shown). Moreover, 
we have confirmed by intracellular cytokine staining the presence of CD4+ T cells 
producing IFN in the spleen cells of mice immunized and challenged with the 
citrullinated peptides and not with their non-citrullinated counterparts (data not shown). 
As expected, peptide-specific responses were impaired in the presence of anti-HLA-
DR antibodies, confirming that the responses against citrullinated vim5 and 31 are 
HLA-DR restricted (Figure 3A&B). Together, these data indicate that the two peptides 
identified induce a “citrulline”-specific T cell response in a HLA-DRB1*0401 
restricted manner. 
Natural processing of the immunogenetic peptides from citrullinated vimentin 
protein 
To analyze whether the citrullinated peptides recognized by T cells can be naturally 
processed and presented from the entire vimentin protein, we next tested the reactivity 
of spleen cells from peptide-immunized mice against the recombinant human vimentin 
either in citrullinated or non-citrullinated form. In three independent experiments, a 
significant response against the citrullinated vimentin protein compared to the medium 
or non-citrullinated protein (Figure 3C) was observed with spleen cells from mice 
immunized with citrullinated vim5. Similar results were obtained with spleen cells 
from mice immunized with vim31 (Figure 3D). No reactivity was observed when 
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not shown). These results indicate that the epitopes identified can be naturally 
processed from citrullinated vimentin. 
Recognition of both vim5 and vim31 by T cells in RA peripheral blood 
Next, we wished to analyze whether the two citrullinated vimentin peptides, vim5 and 
31, identified as DRB1*0401-restricted T cell epitopes in DR4-transgenic mice can be 
recognized by T cells from RA patients. Because the presence of IgG ACPA in patients 
implies the existence of memory T-helper cell responses that have provided help to 
ACPA-producing B cells, we have investigated, as a first inventory, the presence of T 
cells with a memory phenotype specific for vim5 or vim31 in 10 ACPA+ HLA-
DRB1*04+ RA patients from the Leiden Early Arthritis Cohort (EAC) (Patient 
characteristics are shown in Table 1). PBMC from these patients were tested for IFN 
production by intracellular cytokine staining after stimulation with (citrullinated) vim5 
or 31. After gating of the CD3+CD4+CD45RA- lymphocytes, cells from three of the 
patients responded to citrullinated but not against non-citrullinated vim5 (Figure 
4A&B). Next to the patients, also five healthy controls were tested. The percentages of 
CD3+CD4+CD45RA- cells producing cytokines were much lower compared to the 
patients and no significant differences between the different culture conditions were 
observed (Figure 4B, right panel). From the nine RA patients tested for (citrullinated) 
vim31 reactivity, a marginal, but detectable, response was observed for three patients 
(Figure 4C and 4D, left panel). From these three patients, one also responded to the 
non-citrullinated peptide, although to a less extent. In contrast, no responses were 
observed against both citrullinated and non-citrullinated vim31 in the healthy 
individuals (Figure 4D, right panel). All patients and controls showed T cell reactivity 
against a control antigen (Memory Mix, data not shown). These data suggest that both 
identified vimentin epitopes can be recognized by T cells from ACPA+ HLA-
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Discussion 
At present, only limited data are available on potential T cell epitopes that can be 
recognized in a “citrulline’-dependent manner by RA patients. Therefore, an unbiased 
inventory, focusing on relevant autoantigens recognized by ACPA, such as performed 
in the experiments described in this manuscript is highly relevant. 
We examined in this study whether we could identify CD4+ T cells specific for 
citrullinated peptides derived from human vimentin. In total 33 peptides were 
synthesized in their citrullinated form and tested for T cell reactivity in DR4-transgenic 
mice. A “citrulline”-specific response was observed against two of the peptides, vim5 
(vim26-44) and vim31 (vim415-433). We have shown that these peptides are naturally 
processed epitopes of human vimentin and provided data indicating that they can be 
recognized by T cells with a memory phenotype from RA patients. 
 
The two T cell epitopes identified in this study have not been described before to be 
either involved in B cell or T cell responses. Previous studies identified T cell 
reactivity against a vimentin-derived peptide in HLA-DR4-positive mice (29). 
Although the peptide sequence used by Hill et al. was similar, it was not homologous 
to the sequence present in vimentin (30). A (large) Leucine present in vimentin 
(position 69), was replaced by the small Alanine, thereby possibly influencing the 
binding capacity to the HLA molecule (31). Our study identifies two vimentin epitopes 
that can be recognized by HLA-DRB1*0401 restricted T cells without the apparent 
requirement for additional amino acid changes, such as described by Hill et al. 
Furthermore, the peptide of the study by Hill et al. was selected on the basis of a 
prediction program focusing on the ability of Arginine/Citrulline to bind the anchor 
region shared by the SE-containing HLA-DRB1 alleles. We, however, used an 
unbiased approach in which all possible peptides from the vimentin protein were tested 
by positioning every Arginine present in the middle of a peptide. Although the 
Arginine is centred, it can bind to every anchor position of the binding pocket since the 
peptide is 19 amino acids long. 
 
The observed T cell responses in HLA-DR4 transgenic mice are HLA-restricted, as 
shown using an HLA-DR-blocking antibody. However, these IFN-responses are only 
partially blocked in the presence of the anti-HLA-DR antibody. This is probably due to 
the high abundance of HLA-DR molecules on the cell surface of antigen-presenting 
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the capacity of this antibody to inhibit T cells responses was previously shown to vary 
depending on the DR molecule involved (32).  
Because binding of the peptides to the HLA-DR4 molecule is indispensable for 
induction of a T cell response, we tested for both citrullinated and non-citrullinated 
vim5 and 31 their binding to HLA-DRB1*0401 in a competitive binding assay using 
the biotinylated HA-peptide (HA309-320) as a competitor. Only weak inhibition of the 
biotinylated peptide could be observed at high peptide concentrations (data not shown). 
Therefore, no conclusions could be drawn about the differences in binding capacity 
between the identified citrullinated and non-citrullinated version of the vimentin 
peptides to the HLA-DR4 molecule. This observation is in line with other observations 
showing that low affinity peptides can also efficiently induce T cell responses, as is 
described for an insulin peptide in NOD mice (33) and recently for a dominant gluten 
peptide in DQ8-transgenic mice (34). A low net binding value to MHC class II can be a 
consequence of both the association and dissociation rate with the MHC molecule 
being high, while the T cell response is readily observed (34-36). Although our results 
might be counterintuitive, they are very intriguing as it has been proposed that low 
affinity peptides play an important role in the induction of autoimmunity since they 
escape tolerance induction (37;38). 
 
The IFN production observed with PBMC from RA patients was rather low. However, 
this would be in line with the view that the expected precursor frequency of T cells 
reacting with citrullinated vimentin peptides is low. Even the T cell fraction reactive to 
recall antigens (i.e. a mix of Tetanus Toxoid, Candida Albicans and tuberculin purified 
protein derivative) is only 3% on average after restimulation. Furthermore, it has been 
shown that PBMC from RA patients produce less IFN compared to healthy 
individuals in response to recall antigens, probably due to immuno-suppressive drugs 
(39). 
In this study, we have performed an inventory of T cell responses against the identified 
epitopes in 10 ACPA+ HLA-DRB1*04+ RA patients and 5 HLA-DRB1*04+ healthy 
controls. To obtain a comprehensive view of the pattern of reactivity of citrullinated 
vimentin-specific T cells, several different aspects remain to be elucidated in a larger 
cohort of patients and controls. Future studies include assessing recognition of these T 
cell epitopes in ACPA+, as well as ACPA- patients, and the requirement for SE-
containing HLA-DRB1 alleles for the recognition. Likewise, a more extensive 
characterization of the cytokine profile of these T cells would be informative, as it is 
conceivable that the cytokine profile changed from a regulatory type in healthy controls 
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to pro-inflammatory in RA patients as it was previously  shown for another RA 
candidate autoantigen (39). Furthermore, since our approach focused specifically on 
the identification of “citrulline”-specific T cells, it cannot be excluded that also T cells 
reacting against non-citrullinated peptides from the vimentin protein or another protein 
that is internalized and presented together with citrullinated vimentin exist. These 
studies would involve immunization with non-citrullinated peptides from vimentin or 
other proteins that could be associated with vimentin in vivo. All these aspects imply 
the necessity of further extensive studies. Nonetheless, our study is the first to identify 
“citrulline”-specific T cell responses in humans, recognizing epitopes from an 
autoantigen present in the inflamed joint of RA patients. As such, these results provide 
a valuable basis for future, more extensive studies. 
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Abstract 
  
Objectives. Anti-citrullinated peptide antibodies (ACPA) and the C1858T missense 
single-nucleotide polymorphism (SNP) in the PTPN22 gene are both associated with 
the development of rheumatoid arthritis (RA). We investigated whether the 
combination of these two biomarkers yielded better test characteristics to predict 
progression from undifferentiated arthritis (UA) to RA compared to ACPA alone. 
Methods.  Three-hundred ninety-four individuals with UA from a Dutch population-
based inception cohort were included in this study. At baseline ACPA were measured 
and the PTPN22 C1858T and HLA-DRB1 genotypes determined.  Progression to RA 
was monitored at one year after entry into the cohort. 
Results. A priori, UA patients had a 35% (95% CI 30-40%) risk of developing RA, 
which increased to 66% (95% CI 57-75%) in patients who were ACPA-positive. There 
was an additional although non-significant (p = 0.34) increase in RA risk to 76% 
(95%CI 57-90%) when patients were positive for both ACPA and the PTPN22 1858T-
allele. The area under the receiver operator characteristic curve increased from 0.68 for 
ACPA-status alone to 0.70 for the combination of ACPA-status and the PTPN22 
C1858T polymorphism. In logistic regression analysis, ACPA predicted RA-
development independent of PTPN22, while the PTPN22 polymorphism had no 
independent effect. In HLA-DRB1 shared epitope positive, ACPA-positive UA 
patients, ACPA-levels were significantly increased in PTPN22 1858T allele carriers 
compared to non-1858T carriers. 
Conclusions. In this Dutch cohort of UA-patients, the PTPN22 1858T allele does not 
markedly improve individual decision-making to predict RA-development over ACPA 





Risk of progression from UA to RA  73 
Introduction 
Anti-citrullinated peptide antibodies (ACPA), which can be detected years before 
disease onset, are highly specific for rheumatoid arthritis (RA) (1-3). Approximately 
72% of patients presenting with an early form of arthritis that cannot be properly 
classified (undifferentiated arthritis, UA) and who are positive for ACPA develop RA 
(4). The C1858T missense single-nucleotide polymorphism in the PTPN22 gene is also 
associated with RA, UA (5-11) and several other autoimmune diseases (for a review 
see 12). The relevance for ACPA-determination is increasingly accepted in clinical 
practice (3); however, the role of the PTPN22 1858T-allele in RA prediction has not 
been studied. Consequently, we investigated whether the combination of these two 
biomarkers improved prediction of progression from UA to RA compared to ACPA 
alone. Since the PTPN22 1858T-allele confers risk to ACPA-positive arthritis (10) we 
hypothesized that the PTPN22 C1858T polymorphism may also influence auto-
antibody levels. Therefore we examined whether ACPA-levels differed between 
ACPA-positive UA-patients with and without the PTPN22 T-allele. 
 
Material and Methods 
Study population.  
The Leiden Early Arthritis Clinic (EAC) is a population-based inception cohort of 
white Dutch patients with recent-onset arthritis (median symptom duration 112 days, 
IQR 55-239 days) which, at present, includes 1944 individuals (for a detailed 
description of this cohort see ref 13). A subset of these patients (n=394), who could not 
be classified according to the 1987 ACR criteria at baseline and were categorized as 
having undifferentiated arthritis (UA), were included in this study. At one year of 
follow-up, subjects were re-evaluated as having RA or not according to the ACR 1987 
criteria (14). Patients who during the one year of follow-up cumulatively fulfilled the 
ACR criteria were diagnosed as RA and all other patients as non-RA.  
Laboratory methods.  
Blood specimens, obtained at baseline, were typed for anti-CCP2 antibodies (ACPA) 
using an ELISA (Immunoscan RA Mark 2; Euro-diagnostica, Arnhem, The 
Netherlands). The cut-off level for ACPA positivity was set at 25 arbitrary units, 









Figure 1.  Characteristics of the study population. A. Description of the patient cohort. The RA 
diagnosis is based on the diagnosis after 1 year of inclusion in the cohort. UA=undifferentiated 
arthritis, n=number of patients in this group. B. Proportional values for RA-development taking 
into account ACPA status (positive or negative), the PTPN22 C1858T-polymorphism (T-allele 
positive or negative) or a combination of these two markers. PPV = positive predictive value, 
NPV = negative predictive value.     
Sensitivity Specificity PPV NPV  
% 95% CI % 95% CI % 95% CI % 95% CI 
ACPA 50 42-58 86 82-90 66 57-75 76 71-81 
PTPN22 21 14-28 77 72-83 33 23-43 64 59-70 
PTPN22 given ACPA+ 32 21-44 81 64-92 76 57-90 38 27-50 
PTPN22 given ACPA- 10 4-20 77 71-82 12 5-23 73 67-79 
UA(2 weeks) 
N=394 
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1 year risk of RA= 62%  
             (95%CI 50-73%) 
PTPN22+ n= 58 
RA n=7 
Non-RA n=51 
1 year risk of RA= 12%  
               (95%CI 5-23%) 
PTPN22- n= 231 
RA n=62 
Non-RA n=169 
1 year risk of RA= 27%  
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measured at baseline with an ELISA. The PTPN22 C1858T polymorphism and HLA-
DRB1-alleles were genotyped as previously described (5,15). 
Analysis.  
Statistical analyses were performed using SPSS_12.0 Software (Chicago, IL, USA). 
95% confidence intervals (95%CI) of the proportional data were calculated with CIA 
software (16). Predictive values were compared by logistic regression analysis and by 
determination of the area under the receiver operator characteristic curve (AUC). The 
Mann-Whitney test and linear regression analysis were used to compare ACPA levels. 
 
Results 
Of the 394 UA patients, 138 patients (35%) progressed to RA within one year (Figure 
1A). Of these 138, 69 (50%) were positive for ACPA at baseline, compared to 36 of 
the 256 individuals (14%) in the non-RA group. The PTPN22 1858T-allele was present 
in 21% (n=29) of UA-patients who progressed to RA and in 23% (n=58) of the non-RA 
group. The unadjusted relative risk (RR) for RA-development was 2.75 (95%CI 2.15-
3.53) for ACPA-positivity and 0.94 (95%CI 0.67-1.31) for carriage of the PTPN22 
1858T allele. 
Of the 105 ACPA-positive patients, 66% (95%CI 57-75%) developed RA in 1 year, 
compared to 24% (95%CI 19-29%) of the 289 ACPA-negative patients. When the 
ACPA-positive and ACPA-negative patient groups were further stratified for PTPN22 
1858T allele carriage, 76% (22 of 29, 95%CI 57-90%) of the ACPA-positive, PTPN22 
1858T-allele positive patients developed RA, compared to 62% (47 of 76, 95%CI 50-
73%) of the ACPA-positive PTPN22 1858T-allele negative patients. Although these 
results show an increased predictive value if the PTPN22 C1858T polymorphism is 
combined with ACPA status, this difference was not statistically significant (p=0.34). 
While ACPA-negative patients had a 24% risk of progressing to RA, information on 
the presence or absence of PTPN22 1858T allele did not significantly alter this 
probability (Figure 1A). A similar analysis examining the effect of the PTPN22 1858T 
allele conditional on baseline levels of rheumatoid factor showed no significant 
differences in the probabilities for developing RA (data not shown). 
To further understand the role of ACPA and the PTPN22 1858T allele in RA risk 
prediction, we used logistic regression analysis to examine how these factors 
influenced risk for RA-development, mutually adjusting for both the presence of 
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independent predictive variable in this model (OR 6.3, 95%CI 3.9-10.3, p<0.0001), 
whereas the PTPN22 1858T-allele was not (OR=0.7, 95% CI 0.4-1.3, p=0.282). 
Addition of the PTPN22 C1858T polymorphism to ACPA status in the regression 
model increased the AUC marginally (AUC 0.68 for ACPA alone and 0.70 for both). 
 
Because we previously observed a stronger association of the PTPN22 C1858T 
polymorphism with ACPA-positive RA than ACPA-negative RA (10), we stratified 
and compared the ACPA levels of all 96 ACPA-positive subjects according to PTPN22 
1858T carriage status. As HLA-DRB1 alleles that encode for a common amino acid 
sequence, the shared epitope (SE), dominantly influence the level of ACPA (4), this 
analysis was performed after stratification for the presence or absence of SE-alleles 
(defined as DRB1*0101, 0102, 0401, 0404, 0405, 0408, 0410, 1001 or 1402). Within 
the 71 SE-positive ACPA-positive patients, the 22 carrying the PTPN22 1858T allele 
had significantly higher levels of ACPA (median 1190 units, IQR 286-1970 units) 
compared to the 49 who did not carry this allele (median 357 units, IQR 152-988 units) 
Figure 2.  Influence of PTPN22-polymorphism on anti-CCP (ACPA) levels.  
Ninety-six of the 105 UA patients who had ACPA were successfully genotyped for the 
DRB1 Shared Epitope (SE) alleles (defined as DRB1*0101, 0102, 0401, 0404, 0405, 0408, 
0410, 1001 and 1402) and both SE+ and SE- patients were divided in two groups based on 
the presence or absence of the PTPN22 1858T allele. Only the SE+ patients are shown in 
the graph.  
n = number of patients in each group, AU=arbitrary units. The lines represent the median 
of the ACPA antibody levels in each group. 
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(p=0.04) (Figure 2). No difference by PTPN22 1858T allele was observed among the 
SE-negative patients (SE-PTPN22- n= 21, median 346 units, IQR 80-1712 units; SE-
PTPN22+, n=4 median 584 units, IQR 43-1848 units); however, the sample sizes were 
too small to draw a statistically sound conclusion. Linear regression analysis adjusting 
for HLA-SE confirmed the independent association of the PTPN22 C1858T 
polymorphism with ACPA levels in ACPA positive patients (B= 452 units, 95%CI 58-
847 units, p=0.03). 
 
Discussion 
Previous studies showed that the PTPN22 C1858T polymorphism and ACPA-status are 
both associated with development of RA in the general population (1,2,5-11). Our 
study demonstrates an independent association of ACPA but not the PTPN22 1858T 
allele with progression to RA among patients presenting with UA. 
Johansson et al. observed that the specificity for future onset of RA in a population of 
healthy blood donors increased from 98.6%, when only ACPA-status was taken into 
account, to 100% when both ACPA and PTPN22 C1858T polymorphism were 
analyzed together (17). They did not determine the sensitivity and specificity of 
subsequently APCA alone and the combination of ACPA and the PTPN22 1858T 
allele, but compared the patients positive for both ACPA and the PTPN22 1858T allele 
with all other patients (including patients positive for either ACPA or the PTPN22 
1858T allele or negative for both). This resulted in different values for specificity and 
sensitivity compared to this study. Since the value of a positive test result as for an 
individual patient in clinical practice is not measured by the sensitivity or specificity, 
but is reflected by the a priori and post priori probabilities, the current study evaluated 
the risk of a cohort of patients presenting with UA to progress to RA given their ACPA 
and PTPN22 1858T status. The risk to develop RA increased significantly in the case 
of ACPA-positivity. This risk increased marginally for those ACPA-positive patients 
who also harbored the PTPN22 1858T allele; however, this increase was not 
significant. We cannot exclude a Type-II error although, given the effect size, 
approximately 3000 UA-patients, from which approximately 800 are ACPA positive, 
would be needed to detect a significant difference. In the ACPA-negative group, 
knowledge of the PTPN22 C1858T polymorphism did not increase the predictive value 
of RA development. Moreover, only ACPA was identified as a significant independent 
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the PTPN22 polymorphism in addition to ACPA-status will be of limited relevance for 
patients with UA. 
The notion that for clinical practice testing of the PTPN22 C1858T polymorphism has 
no additive value to ACPA-determination is not in contrast with the findings that the 
PTPN22 C1858T polymorphism is involved in the pathogenesis of RA. The PTPN22 
C1858T polymorphism is only associated with ACPA-positive RA, indicating that the 
PTPN22 genotype confers risk to a serologically defined subset of RA. Thus, 
pathophysiologically both factors are on the same pathway, and by measuring ACPA 
the effect of the PTPN22 1858T-allele when present, is already included. 
It should also be noted that, given there is a gradient in the frequency of the PTPN22 
1858T allele that increases from the south (2-3% in Italy) to the north (15.5% in 
Finland) (for a review see 12) of Europe, the utility of the SNP may vary in different 
populations. 
We also showed that the presence of the PTPN22 1858T-allele in shared epitope 
positive, ACPA positive UA-patients was associated with higher levels of ACPA. This 
is of interest as a recent study revealed that ACPA-levels were a predictor for RA-
development in ACPA-positive UA-patients (18).  The observation that ACPA-positive 
patients who carry the PTPN22 disease-associated 1858T-allele have higher ACPA-
levels than those who are homozygous for 1858C is interesting and may shed some 
light on how the PTPN22 1858T polymorphism, which appears to be a “gain of 
function” allele, mediates susceptibility to multiple autoimmune diseases (5,19,20). 
Given the findings of this study we conclude that (i) testing for the PTPN22 C1858T-
polymorphism in ACPA-positive UA-patients does not significantly improve 
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Abstract 
  
Objective: The severity of joint destruction in Rheumatoid Arthritis (RA) is highly 
variable between patients and influenced by genetic factors. Genome-wide association 
studies (GWAs) have boosted the field of the genetics of susceptibility to RA 
enormously, but risk loci for severity of RA remain poorly defined. A recent meta-
analysis of GWAs identified 6 genetic regions for susceptibility to autoantibody-
positive RA, i.e. CD40, KIF5A-PIP4K2C, CDK6, CCL21, PRKCQ and MMEL1-
TNFRSF14. We have investigated whether these newly described genetic regions 
associate with the rate of joint destruction.   
Methods: RA-patients enrolled in the Leiden Early Arthritis Clinic were studied 
(n=563). Yearly radiographs were scored using the Sharp-van der Heijde method 
(median follow-up 5 years, maximal follow-up 9 years). The rate of joint destruction 
between genotype groups was compared using a linear mixed model correcting for age, 
gender and treatment-strategies. 393 ACPA-positive-RA-patients included in the 
NARAC with radiographic data were used for replication. 
Results: The TT and CC/CG genotypes of two SNPs, rs4810485 (CD40) and rs42041 
(CDK6) respectively, were associated with a higher rate of joint destruction in ACPA-
positive RA (p=0.003 and 0.012), of which rs4810485 was significant after Bonferroni 
correction for multiple testing. The association of the CD40 minor allele with 
radiographic progression rate was replicated in the NARAC cohort (p=0.021).    
Conclusion: A polymorphism in the CD40 locus is associated with the rate of joint 
destruction in ACPA-positive RA and provides one of the first non-HLA-related 
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Introduction 
Rheumatoid arthritis (RA) is characterized by inflammatory arthritis and localized 
destruction of bone and cartilage. The severity of joint destruction is highly variable 
between patients and, according to twin studies, substantially influenced by genetic 
factors (1). Nevertheless, the precise contribution of genetic factors still has to be 
determined. To date only a small number of genetic risk-factors has been identified, 
and apart from HLA, none of these factors have been convincingly replicated. 
  
In contrast, the genetics of susceptibility to RA has been boosted considerably, largely 
due to genome-wide association studies. In addition to the HLA-DRB1 shared epitope 
alleles, several new susceptibility-factors, PTPN22, TRAF1-C5, OLIG3-TNFAIP3 and 
STAT4, have been identified and were independently replicated. Intriguingly, for many 
of these genetic risk-factors the associations are confined to anti-citrullinated protein 
antibodies (ACPA)-positive RA-patients. Whether genetic factors also differently 
affect the severity of joint destruction in ACPA-positive and ACPA-negative RA 
remains unknown. Nonetheless, compelling evidence demonstrates that ACPA-positive 
RA-patients have a more destructive disease course compared to ACPA-negative 
patients.  
 
A recent meta-analysis on two genome-wide association studies identified six new risk 
loci (rs4810485 (CD40), rs1678542 (KIF5A-PIP4K2C), rs42041 (CDK6), rs2812378 
(CCL21), rs4750316 (PRKCQ) and rs3890745 (MMEL1-TNFRSF14)) as susceptibility 
factors for autoantibody-positive RA (2). The present study aimed to investigate the 
association between these single-nucleotide-polymorphisms (SNPs) and the rate of 
radiological joint destruction in RA, and ACPA+ RA in particular, using a large 
longitudinal cohort. A cohort of ACPA-positive RA-patients was used for replication. 
This study shows that a genetic variant in the CD40 gene associates with the rate of 
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Patients and methods 
Patients 
Five hundred sixty three RA-patients, consecutively included in the Leiden Early 
Arthritis Cohort (EAC) between 1993 and 2006 with both DNA and radiographs 
available were studied. The RA-patients fulfilled the 1987 ACR-criteria. Follow-up 
visits were performed yearly. Treatment strategies changed in time and differed for 
different inclusion periods (before 1996, 1996-1998, 1999-2001, after 2001) (see 
ref (3) for detailed description of the EAC). Anti-CCP2 antibodies were measured 
using stored baseline serum samples (Immunoscan RA Mark 2; Euro-Diagnostica, The 
Netherlands). 
Replication cohort 
393 ACPA-positive RA-patients that were included in the North American Rheumatoid 
Arthritis Consortium (NARAC) that had hand radiographs available were studied. As 
the radiographs were taken at different disease durations, the estimated radiological 
progression per year was determined by dividing the total Sharp-van der Heijde score 
of the hands by the disease duration at the time of the radiograph.  
SNP genotyping 
The six recently identified risk loci (2) were genotyped in the 563 RA-patients from the 
Leiden EAC using allele-specific kinetic PCR as previously described (4). The data 
were hand-curated without knowledge of clinical characteristics before statistical 
analysis with a 98% genotyping success rate; previous analyses suggest a genotyping 
accuracy of >99%. For the MMEL1-TNFRSF14 locus, a perfect proxy of rs3890745 
(reported in (2) )  was used (rs6684865, r2=1). 
In the NARAC genotyping was performed using the Illumina Hapmap500 BeadChip, 
as described (5). Rs4810485 was not typed in the whole genome study, but a perfect 
proxy for this variant was genotyped (rs1569723, r2=1). For CDK6, neither rs42041 nor 
a perfect proxy were genotyped and therefore the data on rs42041 was imputed as 
described (2).  
Radiographs 
In the EAC, radiographs of hands and feet, taken on consecutive years, were scored 
according to the Sharp-van der Heijde method (6). To encompass a reliable sample 
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size, radiographic follow-up data were restricted to a maximum of 9 years with a 
median of 5 years. All radiographs were scored by one experienced scorer who was 
blinded with respect to clinical and genetic data. 499 radiographs were rescored (149 
baseline radiographs and 350 radiographs during follow-up from 60 randomly selected 
RA-patients). Intraclass-observer correlation coefficients (ICC) were 0.91 for all 
radiographs, 0.84 for baseline radiographs and 0.97 for the radiographic progression 
rate. In the NARAC the radiographs were scored by one reader blinded to clinical or 
genetic data. 25% of the radiographs were re-scored, the ICC was 0.99. 
Statistical Analysis 
Analyses were performed using SPSS version 16.0 (SPSS Inc., Chicago, IL). As 
radiographic data were not normally distributed, the raw data on the Sharp-van der 
Heijde scores are presented using medians (Figure 1-2) and were log-transformed in 
preparation for analysis. In the EAC, a linear model for longitudinal data was used to 
compare progression rates between groups. Age, gender, inclusion period (a proxy for 
treatment strategy) and their interactions with time were entered in the model to correct 
for possible confounding effects (see also the supplementary methods). As six SNPs 
were evaluated, a Bonferroni correction for multiple testing was applied; the p-value 
for significance was set at p<0.008. Only the SNPs that were clearly related to the 
progression rate in the EAC were analyzed in the replication cohort. In the NARAC, 
the estimated radiological progression per year was compared with the Kruskal Wallis 
test. No corrections were made for age, gender or treatment in this cohort. 
 
Results  
Baseline characteristics of the RA-patients are shown in Table 1. In the EAC, the 
minor allele frequencies were 0.242, 0.340, 0.267, 0.366, 0.204 and 0.307 for 
rs4810485, rs1678542, rs42041, rs2812378, rs4750316 and rs6684865 respectively and 
in agreement with previous results (2). The raw data on the Sharp-van der Heijde 
scores for the three genotypes at each SNP are depicted in Figure 1. To study the 
influence of the SNPs on the rate of joint destruction, a linear mixed model analysis 
was performed for each SNP. For rs4810485 (CD40) the GG and GT genotypes 
showed comparable radiographic scores, therefore the genotype data were combined 
and carriership-analysis was performed. Similarly, the CC and CG genotypes of 
rs42041 (CDK6) were pooled. In the total group of RA-patients an association was 
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† Data on ACPA-, RF- and HLA DRB1 SE-status and CRP and ESR-levels were 
available in the EAC in 447, 551, 441, 520 and 544 out of 563 genotyped patients 
respectively.  
§ Data on ACPA- and HLA DRB1 SE-status was available for all of the 393 genotyped 
patients. 
 
Patient Characteristics EAC  N=563 
Age at inclusion (yrs), mean (SD)  56.0 (± 15.6) 
Female, N (%)  394 (70.0) 
Symptom duration at inclusion (months), mean (SD)  6.7 (± 10.5) 
Swollen Joint Count, mean (SD)  5.72 (± 3.3) 
Ritchie score, mean (SD)  10.3 (± 7.8) 
ACPA-positive, N (%)†    250 (55.9) 
IgM-RF-positive, N (%)†   322 (58.4) 
HLA-DRB1 Shared Epitope +, N (%)†  339 (67.1) 
CRP (mg/l), mean (SD)†  29.4 (± 34.2) 
ESR (mm/h), mean (SD)†  39.5 (± 27.5) 
HAQ, mean (SD)  1.1 (± 0.7) 
Total Sharp-score, median (IQR)   5 (2-11) 
Patient Characteristics NARAC  N=393 
Age at disease onset  40.8 (± 11.9) 
Female, N (%)  286 (72.8) 
ACPA-positive, (%)§  100% 
HLA-DRB1 Shared Epitope +, N (%)§  100% 
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with the radiological progression over time was detected (p=0.268, 0.369, 0.679, 0.583 
and 0.451 for rs4810485, rs1678542, rs2812378, rs4750316 and rs6684865 
respectively). Because the genetic regions studied are thus far observed to be 
susceptibility-factors only for autoantibody-positive RA-patients, analyses were 
repeated in the ACPA-positive subgroup. Here, two polymorphisms, rs4810485 
(CD40) and rs42041 (CDK6), affected the rate of joint destruction (Figure 2). For 
rs4810485, the G-allele was associated with a lower progression rate (GG/GT vs. TT, 
p=0.003). Back transforming the regression coefficient of the genotype in the model to 
the original scale yielded a 1.12 (95% CI 1.04-1.21) times larger increase in Sharp-
score per year for carrying the risk genotype. For rs42041, the C-allele was associated 
with a higher rate of joint destruction (CC/CG vs. GG, p=0.012). For carriership of the 
C-allele a 1.09 (95% CI 1.02-1.16) larger yearly increase in Sharp-score was observed. 
Only rs4810485 was statistically significant after correction for multiple testing. The 
interaction between inclusion period and time was significant in all six analyses 
(p<0.001), demonstrating the effect of inclusion period on the radiological progression 
rate. Gender and age were not independently associated with progression.  
 
To find replication, the effect of CD40 and CDK6 on radiological progression was 
analysed in 393 ACPA-positive RA-patients from the NARAC. Using a perfect proxy 
for rs4810485, the genotype associated with severity in the EAC also revealed a higher 
estimated radiological progression per year in the NARAC: 3.40 Sharp-units/year 
(n=23) vs. 2.83 and 1.83 Sharp-units/year (n=122 and 248, p=0.021). Using imputed 
data for rs42041 no significant differences between the three genotypes were observed 
(2.76, 2.38 and 2.07 Sharp-units/year, n=32, 163 and 188 respectively, p=0.327). The 
total number of patients available for analysis of rs42041 was 383; genotyping data 
were missing in 10 cases. 
 
Discussion 
Although several clinical and serological risk factors for RA-severity are known, thus 
far the inter-individual variance in joint destruction is insufficiently explained and 
genetic factors are scarcely investigated. A better comprehension of the factors that 
mediate joint damage in RA may lead to the development targeted therapies or may 
contribute to prediction of the disease outcome in individual RA-patients.  Most 
recently, six new loci were described to predispose to autoantibody-positive RA (2). 
























































































































































































































































































































































































































































































































































































































investigated whether these six SNPs are also risk-factors for a severe course of RA, 
measured by the rate of joint damage. The present data suggest that two SNPs, 
rs4810485 (CD40) and rs42041 (CDK6), influence the rate of joint destruction in 
ACPA-positive RA. Of these, only rs4810485 was significantly associated after 
correction for multiple testing and was replicated in an independent cohort of ACPA-
positive RA-patients. As such, CD40 is the first non-HLA-related genetic risk-factor 
for RA-severity that is independently replicated.  
Overview of the raw Sharp-van der Heijde scores, expressed as medians, in ACPA-positive RA 
(n=250). The G-allele was the risk-allele predisposing to RA in the study of Raychaudhuri et al (2) 
for both the rs4810485 and rs42041 SNPs. The number of patients in the different genotype groups 
were for rs4810485*: GG: 128, GT: 88, TT: 11 and for rs42041: CC: 131, CG: 101, GG: 18. 
*genotype data for rs4810485 was not available in 23 cases. SHS: Sharp-van der Heijde score. 
Figure 2  Median Sharp-van der Heijde scores for rs4810485 and rs42041  
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A recent study (2) reported a common variant at the CD40 locus (the minor T-allele) to 
be protective for the development of RA. Surprisingly, here the minor T-allele 
associates with a higher rate of joint destruction in two cohorts. This finding is counter-
intuitive, if one assumes that genetic variants associating with susceptibility also 
associate with severity. Although our findings were observed in two independent 
cohorts, and thus replicated, a type I error cannot be ruled out. The disease associated 
(common) allele marks a haplotype of CD40 that contains a polymorphism in the 
upstream Kozak sequence that results in increased surface expression on B cells (7). To 
our knowledge, the effect of this haplotype on CD40 surface expression in synovial 
fibroblasts has not been directly studied. However, CD40-expression is increased on 
synoviocytes in RA and triggering of CD40 in synovial fibroblasts is associated with 
production of proinflammatory cytokines and osteoclastogenesis (8;9). It is likely that 
the biological pathways underlying susceptibility and severity are distinct with respect 
to CD40 triggering. This would provide an explanation for the finding that the minor 
T-allele has a protective effect in susceptibility studies but associates with a more 
severe disease course.  Clearly it is essential to perform further studies on the 
mechanisms by which CD40 polymorphisms associate with erosive outcome in RA.  
 
A second SNP tended to associate with the rate of joint damage in RA in the EAC, 
rs42041. Absence of replication in the NARAC indicates that the observed association 
with the progression rate in the EAC cannot be interpreted. Nonetheless, it will be 
interesting to see the results on other studies analyzing CDK6 and RA-severity. Thus, 
at present, of the two SNPs that tended to show an association with the rate of joint 
destruction, only the genetic variant in CD40 is statistically significant after correction 
for multiple testing and is replicated and is therefore identified as a severity-factor for 
RA. 
 
The other four studied SNPs in the loci encoding for KIF5A-PIP4K2C, CCL21, 
PRKCQ and MMEL1-TNFRSF14 were not observed to associate with the severity of 
joint destruction. Therefore, these polymorphisms appear to be genetic risk-factors that 
are primarily associated with RA-susceptibility. Indeed, all of these SNPs were 
recently replicated as true susceptible loci in RA-patients of European ancestry (10). 
 
The prospective nature of the data of the EAC strengthens the impact of the findings 
because higher radiological scores for risk-genotypes were present at subsequent time 
points; as such the present data set is advantageous in comparison to studies that 
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assessed cross-sectional radiological data. The fact that a large number of patients with 
a long follow-up of up to 9 years were included for analysis is clearly an advantage, but 
also has a limitation. Inherent to the design of an inception cohort, not all patients had 
achieved maximum follow-up, so the number of missing data that the mixed-model had 
to take into account increased with longer follow-up. Small numbers of radiographs 
available at the latest time points are also the most likely explanation for the observed 
“bump” at the 8 year time point for the genotypes GG, CC and TT of the SNPs 
rs2812378, rs4750316 and rs6684865 respectively (Figure 1).   
 
Evaluation of the effect of genetic factors on the rate of joint destruction during the 
disease course inevitably implies that other factors that affect the disease course should 
be taken into consideration as well. Analyses for all six SNPs revealed that inclusion 
period, a proxy for treatment strategy, was significantly associated with the rate of joint 
damage, which is in line with previous results from the EAC (11). The analyses on 
CD40 and CDK6 showed that these SNPs were associated with joint damage, 
independent from treatment strategy. Nevertheless, corrections for treatment strategy 
were made on group-level and thus were an approximation for the real effect of 
treatment on the rate of joint destruction for individual RA-patients. 
 
In conclusion, a polymorphism in the CD40 locus shows a significant association with 
the rate of joint destruction in ACPA-positive RA, a finding that is replicated in an 
independent cohort. Although further studies are needed to identify the causal variant, 
the data presented provide a foundation for further investigations of the role of CD40 




To take advantage of the prospective character of the data of the EAC, consisting of 
repeated measurements, and to avoid multiple testing by performing statistical tests for 
each time point, a linear model for longitudinal data was used, with the log transformed 
Sharp-score as response variable, to compare the radiological progression rates 
between genotype groups. Different correlation structures between the repeated 
measurements were explored, and based on the Akaike’s information criterion, an 
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the study design (an inception cohort) not all patients achieved a similar duration of 
follow-up.  The model takes missing observations into account, assuming that the 
missing is at random. Differences in progression rates between the different genotypes 
were tested by considering the significance of the interaction between genotype and 
time with time as linear covariate. Age, gender and inclusion period (before 1996, 
1996-1998, 1999-2001, after 2001) and their interactions with time were entered in the 
model to correct for possible confounding effects. In order to prevent overfitting of the 
data no corrections were applied for other variables. Inclusion period is a proxy for 
treatment modalities, because treatment strategies improved over time and an influence 
of the treatment strategy on the progression of radiographic joint damage was observed 
previously, as well as in the present study. The following treatment strategies were 
applied in the subsequent inclusion periods. Patients included between 1993 and 1995 
were treated initially with analgesics and subsequently with chloroquine or sulfasalazin 
if they had persistent active disease (delayed treatment). From 1996 to 1998 RA-
patients were promptly treated with either chloroquine or sulfasalazin (early treatment) 
(3). From 1998 to 2002 patients were promptly treated with either sulfasalazin or 
methotrexate (early treatment) and patients included in 2002 or later were promptly 
treated with either sulfasalazin or methotrexate combined with treatment adjustments 
based on the disease activity (early and disease activity based treatment). 
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Many cell types take part in the immunological processes contributing to the synovial 
and systemic inflammation present in patients with rheumatoid arthritis (RA), 
including T cells and B cells. They exert their own functions and interact with each 
other, resulting in the chronic inflammation observed in RA. The research presented in 
this thesis focused on the identification of several risk factors and specific T cell 
responses that are thought to play a role in the pathogenesis of RA. 
Four major topics were studied. Firstly, we showed that “DERAA”-containing HLA-
DRB1 alleles are less frequently present in RA patients as compared to controls both 
when these alleles are inherited directly as well as when they are acquired as non-
inherited maternal antigen (NIMA) (Chapter 2 and 3). Secondly, two naturally 
processed epitopes derived from the human citrullinated vimentin protein were 
identified in mice transgenic for the most frequent SE-containing HLA-DRB1 allele in 
Caucasians, HLA-DRB1*0401. IFN-production by CD4+ T cells against these 
peptides could be observed in RA patients (Chapter 4). These T cells could be 
involved in providing help to ACPA-producing B cells. Furthermore, we showed in 
Chapter 5 that the C1858T polymorphism of the PTPN22 gene is not informative for 
the prediction of RA development in UA patients in addition to ACPA status, but does 
seem to affect ACPA-levels of RA patients. In Chapter 6, we observed that a newly 
identified risk factor for RA, CD40, also influences the severity of the disease as 
measured by radiological damage. 
 
Regarding these findings, the following topics will be discussed in further detail in the 
different sections of this chapter: 
1. “DERAA”-containing HLA-DRB1 alleles 
a. The possible mechanism of the observed protection 
b. Maternal michrochimerism as mechanism of the observed NIMA effect 
c. Associations of these HLA-DRB1 alleles with other diseases 
2. PTPN22 and ACPA 
3. The role of CD40 on ACPA production and RA development 
4. Directions for further research 
1a. Possible mechanism of DERAA protection 
It has been shown by several groups that the frequency of “DERAA”-containing HLA-
DRB1 alleles is reduced in RA patients as compared to healthy controls (1-4). We have 
described in Chapter 2 and 3 of this thesis that this protective effect is present both 




98   General discussion 
acquired as a non-inherited maternal antigen (NIMA). Although it is becoming 
increasingly clear that some HLA-DRB1 alleles confer protection to RA (5;6), it is 
unclear whether the entire “DERAA”-motif is essential for protection or whether only 
certain amino acids of this motif may confer the same effect. In contrast to several 
reports showing the protective effects by “DERAA”-containing HLA-DRB1 alleles on 
the development and severity of RA (1-4), other reports conclude that the amino acids 
“RAA” at position 72-74 in the third hypervariable region influence the susceptibility 
to RA development whereas the amino acids at position 70 and 71 modulate this effect 
(7;8). In these articles it is indicated that not only HLA-DRB1  alleles expressing the 
71ERAA74 sequence but also alleles that only contain the Aspartic acid (D) at position 
70 have a lower frequency in RA patients as compared to healthy controls. The 
hypothesis that protection is mainly associated with the Aspartic acid (D) at position 70 
is supported by Ruiz-Morales et al. (9) and Mattey et al (10). A meta-analysis 
including large group sizes and different study populations has to be performed to 
elucidate which of the amino acids are essential for the observed protective effect. In 










The mechanism by which the “DERAA”-containing HLA-DRB1 alleles influence the 
susceptibility to and the severity of RA is unknown, but it has been proposed that it is 
mediated by T cells recognizing peptides containing the “DERAA”-sequence presented 
by HLA-DQ molecules (11). As it is well-known that many peptides presented by 
HLA-class II molecules are derived from other HLA-molecules (12-18), it is 
hypothesized that the T cell repertoire of individuals carrying the “DERAA”-
containing HLA-DRB1 alleles, in contrast to “DERAA”-negative individuals, is 
tolerized for “DERAA”-containing antigens. The “DERAA”-sequence has been 
 Table 1. Human proteins containing the amino acid sequence DERAA. The sequences are  
 depicted as peptides with “DERAA” in the centre and 7 flanking residues on each side. 
Protein name Sequence 
Vinculin     PNREEVFDERAANFENHSG 
MHC QKDI(L/F)LEDERAAVDTYCRH 
Parkin     TTQAYRVDERAAEQARWEA 
PER1 (period circadian protein)     SCLFQDVDERAAPLLGYLP 
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described to be only present in four human proteins (19): i.e. parkin, PER1, the 
“DERAA”-containing HLA-DRB1 molecules and vinculin (Table 1). Parkin and PER1 
are both brain-specific proteins and are therefore probably not involved in the 
protection against RA. It has been shown that vinculin, a cytoskeletal protein, can be 
found under certain conditions (e.g. during apoptosis) on the cell surface, and that 
cross-priming to vinculin-specific cytotoxic T lymphocytes can occur (20;21). These 
findings indicate that vinculin-specific T cells can exist and thus are not tolerized in the 
thymus, despite the fact that vinculin is an abundantly expressed self-protein present in 
the cytoskeleton of every cell in the body. We have observed that PBMC from 
“DERAA”-negative individuals can respond with significantly more IFN to the 
“DERAA”-containing peptide derived from vinculin than those of “DERAA”-positive 
individuals (data not shown). It is hypothesized that the vinculin peptide is recognized 
as self in “DERAA”-positive individuals since the “DERAA”-containing HLA-DRB1 
peptide is presented by another HLA molecule to the immune system, therefore 
resulting either in deletion of vinculin-reactive T cells or skewing of the cytokine 
profile to a suppressive profile without IFN. 
Since it is not likely that IFN-producing T cells reactive against self-proteins are 
induced by such self-proteins, giving rise to autoimmunity, these vinculin-reactive T 
cells possibly result from e.g. an infection. Indeed, the phenomenon that molecular 
mimicry from a pathogen to a self-protein can lead to autoimmunity has been reviewed 
and observed several times (22-28). Many pathogens, such as Influenza, Measles, 
Bordetella Pertussis and Salmonella, can express proteins containing the “DERAA”-
sequence. We therefore hypothesize that “DERAA”-directed T cells stimulated by a 
pathogen-derived “DERAA”-containing peptide accidentally can cross-react with 
human self-proteins, e.g. vinculin. Therefore, they aggravate an ongoing inflammation 
in the joints and play a role in the development of RA (Figure 1). These “DERAA”-
(cross)reactive T cells only exist in “DERAA”-negative individuals (Figure 1A) in 
contrast to “DERAA”-positive individuals (Figure 1B) who are tolerant to the 
“DERAA”-sequence. 
 
Since it was shown that the “DERAA”-containing peptide derived from the HLA-
DRB1*0402 molecule can be presented by HLA-DQ8 (11), evidence supporting the 
hypothesis formulated above was obtained by analyzing T cell reactivity against the 
“DERAA”-containing peptide derived from Influenza A in DQ8-transgenic mice. Our 
preliminary data indicate that T cells specific for the “DERAA”-containing peptide 
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Figure 1. Proposed mechanism for the effect of “DERAA”-containing HLA-DRB1 molecules on 
RA. An individual is infected with a “DERAA”-containing pathogen. Depending on whether it is a 
“DERAA”-negative (A) or a “DERAA”-positive (B) individual T cells reactive with the “DERAA”-
containing peptide processed from the pathogen are triggered or not. These T cells, which are only 
present in “DERAA”-negative individuals (A) can lead together with RA-specific T cells to the 















































Figure 2. Crossreactivity to vinculin in DQ8-transgenic mice. Mice were immunized with the 
“DERAA”-containing peptide derived from Influenza (Influenza) or PBS in adjuvant (Adjuvant). 
Spleen cells were cultured for 4 weeks with the immunizing flu peptide and tested afterwards in a 
proliferation assay with 10,000 cells/well. No (open bars) or anti-HLA-DQ antibodies (hatched 
bars) were added to the wells without stimulation (white bars) or stimulated with the “DERAA”-
containing peptide derived from vinculin (grey bars). Bars represent the mean amount of counts 
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in mice immunized with a control peptide (data not shown). T cells triggered against 
the “DERAA”-peptide derived from Influenza A and cross-reactive with the vinculin-
derived “DERAA”-peptide were HLA-DQ restricted (Figure 2, left part). These T cells 
are absent in mice immunized with adjuvant only (Figure 2, right). Together, these data 
suggest that T cells can show reactivity to the vinculin peptide after initial triggering 
against the “DERAA”-peptide derived from a pathogen, e.g. Influenza A. 
 
When the decreased frequency of “DERAA”-containing HLA-DRB1 alleles in RA 
patients is studied in more detail, several articles showed that “DERAA”-containing 
HLA-DRB1 alleles protect against the development of ACPA+ RA (1;6). Since it has 
been shown that SE-containing HLA-DRB1 alleles associate with the production of 
ACPA and the so-called SE is located at the same position in the HLA-DRB1 molecule 
as the amino acids “DERAA”, this association has to be corrected for the presence of 
SE-containing HLA-DRB1 alleles. Lundstrom et al. showed that also after 
stratification for SE-containing HLA-DRB1 alleles, the frequency of HLA-DRB1*13 
alleles (most frequent “DERAA”-containing HLA-DRB1 alleles) is significantly 
decreased in ACPA+ compared to ACPA- RA patients (29), indicating that the 
“DERAA”-containing HLA-DRB1*13 alleles can  protect against the development of 
ACPA. In a meta-analysis with RA patients and controls from four different countries 
(including our own EAC and BEST cohort) it was shown that HLA-DRB1*1301 
alleles protect against the development of ACPA+ RA in contrast to ACPA- RA after 
stratification for SE-containing HLA-DRB1 alleles. Since the HLA-DRB1*13 alleles 
account for 78-93% of the “DERAA”-containing HLA-DRB1 alleles present in the 
studied patients, the meta-analysis was still underpowered to prove or exclude HLA-
DRB1*0103 and *0402 for the protective effect on ACPA+ RA (30). Therefore, future 
studies have to clarify which HLA-DRB1 alleles confer protection to ACPA. 
1b. Maternal microchimerism as mechanism of the observed NIMA effect 
When the protection induced by both inherited and non-inherited “DERAA”-
containing HLA-DRB1 alleles on RA is working via molecular mimicry, it also could 
explain the mechanism of the NIMA effect. 
In Chapter 2 and 3 of this thesis we hypothesize that the observed NIMA effect of 
“DERAA”-containing HLA-DRB1 alleles is caused by maternal microchimerism. It 
has been shown in humans that there is long-term persistence of microchimerism (31) 
and that these microchimeric cells can differentiate into different tissue-specific cell 
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HLA-molecules on the surface of microchimeric maternal cells the child will recognize 
“DERAA”-containing antigens as self and therefore the observed T cell responses will 
resemble the reactivity of a “DERAA”-positive individual. This will result either in 
regulatory T cells or deletion of “DERAA”-reactive T cells, as occurs with the 
inherited effect of “DERAA”-containing HLA-DRB1 molecules. 
It has been shown that in utero there is a much higher percentage of regulatory T cells 
in the fetus compared to after birth. T cell tolerance to alloantigens (e.g. NIMA) 
present in utero may, in some cases, be maintained after birth through the 
establishment of long-lived regulatory T cells (34). Following this scenario, the 
acquirement of “DERAA”-containing antigens in utero might result in the lifelong 
absence of pro-inflammatory “DERAA”-reactive T cells. 
Another possibility is that the maternal microchimeric cells end up in the thymus 
serving as antigen presenting cell (APC), thereby inducing regulatory T cells or 
deletion of T cells, e.g. against “DERAA”-containing antigens. It is also hypothesized 
by Dutta and Burlingham that it is not the microchimeric APC themselves, but 
maternal antigen acquisition by host APC from these few microchimeric cells that 
drives the balance of T effector and regulatory T cells in favor of the latter (35). 
1c. Effects of “DERAA”-containing HLA-DRB1 alleles in other diseases 
Thus far we have focused on the association of “DERAA”-containing HLA-DRB1 
alleles with RA. We wondered however whether the “DERAA”-containing HLA-
DRB1 alleles might also be associated with other (immunological) disorders. Therefore 
a preliminary literature search was performed to analyze this. The most common 
“DERAA”-containing HLA-DRB1 alleles, HLA-DRB1*13 (from which approximately 
97% will be “DERAA”-containing HLA-DRB1*13 alleles in the Caucasian population 
(36;37)), are associated with Hepatitis B (38-44) and –C infections (45-48), cervical 
cancer (49-54), HIV(55-57)  and systemic lupus erythematosus (58-61). In all these 
different diseases, carriership of HLA-DRB1*13 protects either for the development of 
the disease or chronicity/ complications of the disease. Therefore, “DERAA”-
associated protection does not seem to be specific for RA. It is unknown whether the 
“DERAA”-sequence of the HLA-DR13 molecules is directly involved in the observed 
protection. When future research indicates that these effects can be attributed to the 
presence of “DERAA” in the HLA-molecule, these observations can help to elucidate 
the mechanism by which these “DERAA”-containing HLA-DRB1 alleles can influence 
the immune response. 
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2. PTPN22 and ACPA 
The most studied SNP of the PTPN22 gene is the C1858T polymorphism. This single 
nucleotide change results in an amino acid substitution from Arginine to Tryptophan in 
the Lyp protein transcribed from the PTPN22 gene. This substitution is located in a 
binding domain important for the function of Lyp, which acts as a Tyrosine 
phosphatase (62). The function of Lyp is the negative regulation of T cell receptor 
signaling, either direct or indirect, by influencing the phosphorylation status of 
different molecules involved in the signaling cascade that leads to T cell activation (63-
69). The functional consequences of the amino acid change resulting from the C1858T 
polymorphism are not entirely clear as it has not only been shown that it leads to more 
T cell activation since there is less inhibition of the activation signal by Lyp (70), but 
also that cells from carriers of the T variant produce less cytokine (71). In mice it has 
been shown that a knock-out of Pep, the mouse ortholog of the Lyp protein, displays a 
hyperreactive T cell response (72). Lyp is expressed in different cell types and 
probably exerts different functions in e.g. T and B cells. 
In chapter 5 of this thesis, the predictive value of the C1858T polymorphism was 
studied next to ACPA status. Our study demonstrated an independent association of 
ACPA but not of the PTPN22 C1858T polymorphism with progression to RA among 
patients presenting with UA, although the presence of this SNP is associated with an 
increased level of ACPA in ACPA+ patients. This finding was confirmed by another 
study (73). In many articles, it has been shown that the odds to be a carrier of the T 
variant of the C1858T polymorphism is about two times increased in ACPA+ compared 
to ACPA- individuals, indicating that carriership of the T variant of the C1858T 
polymorphism is associated with ACPA production (74-77). The production of ACPA 
is also associated with the SE-containing HLA-DRB1 alleles. Intriguingly the 
association of PTPN22 with RA is also present only in SE-positive individuals and not 
in SE-negative individuals (76), indicating that SE and the PTPN22 allele are in the 
same biological pathway. As both genetic risk factors associate with ACPA+ disease, 
the contribution of PTPN22 is probably found in setting the balance for ACPA 
production. It is therefore conceivable that PTPN22 associates with ACPA production 
because it has a direct impact on the activity of the B cell receptor as it has been found 
that the T-variant of the C1858T polymorphism results in less B cell receptor signaling 
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Thus, pathophysiologically both the SE-containing HLA-DRB1 alleles, ACPA and 
PTPN22 are players in the same pathway (see Figure 3), and by measuring ACPA the 
effect of the PTPN22 1858T-allele when present, is already included. 
 
 
3. The role of CD40 on ACPA production and RA development 
Recently, a SNP located in the intron of the gene encoding for CD40 was identified to 
associate with RA in a genome wide association study (GWAS) (80). The 
susceptibility allele of this SNP associates with less severity or progression of RA, as 
described in chapter 6 of this thesis. CD40 is a well-known molecule expressed on B 
cells and other antigen presenting cells required for optimal cell activation by T cells. 
Its ligand, CD40L, is expressed on activated CD4+ T cells. Triggering of CD40 is 
involved in B cell proliferation, antibody production, class-switching and B cell 
memory formation. It is unknown what functional consequences the SNP has on the 
expression of CD40 protein, but the effect can be either on the B cell or other 
professional APC such as dendritic cells. Moreover, CD40 is also reported to be 
expressed on synovial fibroblasts. 
Regarding the contribution of CD40 to the process of disease development of RA, it 
can either influence the production of ACPA and thereby the susceptibility and severity 
of RA or play an independent role on the pathogenesis of RA (Figure 3). There is only 
one article on the influence of CD40 on the production of ACPA. In this article it is 
Figure 3. Schematic representation of the risk factors for RA that were studied and 
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shown that B cells from the peripheral blood (both from RA patients and healthy 
controls), synovial fluid and bone marrow all start to produce ACPA in response to 
CD40 triggering. Although B cells from ACPA-positive individuals already produce 
ACPA without in vitro stimulation, the ACPA production is increased after CD40 
stimulation (81). For rheumatoid factor (which are autoantibodies specific for the Fc 
portion of IgG) it has been shown that CD40 signaling plays a major role in the 
survival of rheumatoid factor producing B cells and therefore in the rheumatoid factor 
production (82). 
CD40 signaling into the antigen presenting cell is mediated by the (de)phosphorylation 
of the Tyrosine kinases (83) on which Lyp also exerts its function. Therefore the CD40 
signaling pathway and the effect of the PTPN22 SNP in B cells can probably influence 
each other, and it would by intriguing to know whether a similar relationship between 
CD40 and PTPN22 and/or SE-containing HLA-DRB1 alleles can be formed as 
described for the PTPN22-HLA-SE interaction.  
On the T cell site CD40-CD40L interaction plays an important role in the amplification 
of the T cell response by a positive feedback loop for the production of co-stimulatory 
molecules on dendritic cells (84). 
The role of CD40-CD40L interaction in arthritis has also been studied in different 
mouse models. It has been shown that blocking of the CD40L molecule results in 
prevention of collagen-induced arthritis (CIA), both measured in clinical scoring and in 
the absence of anti-collagen antibodies (85). The inhibition or prevention of arthritis in 
both the K/BxN model and DBA1 mice by prevention of the CD40-CD40L interaction 
has also been shown, but this does not affect established arthritis indicating that the 
CD40-CD40L interaction plays a role in the initiation rather than in the exacerbation 
phase of the arthritis (86-88). 
CD40 is not only expressed on B cells but also on other antigen presenting cells. 
Therefore the influence of CD40 on RA may also be attributable to induction of 
fibroblast proliferation (89), the induction of TNF production by synovial cells (90-
92), chondrocytes (93) or osteoclasts (94). 
 
A sheme showing the relationship of the risk factors studied in this thesis to RA is 
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4. Directions for further research 
As already indicated in several parts of the discussion, future research has to be 
performed to elucidate the phenomena observed and studied in this thesis. Here I will 
indicate future directions that could be followed and that are not mentioned in the 
previous sections. 
“DERAA”-containing HLA-DRB1 alleles protect against the development and severity 
of RA, both when they are inherited and when they are acquired as a NIMA. We 
observed that the effect of the “DERAA”-containing HLA-DRB1 alleles is of a similar 
strength when they are inherited compared to acquired as a NIMA. The underlying 
mechanism of the effect of “DERAA”-containing HLA-DRB1 alleles has been 
discussed in the previous sections but certainly is not proven up to now. The T cell 
reactivity observed against the peptide derived from the human cytoskeletal protein 
vinculin needs to be shown also for naturally processed peptides from the whole 
protein. The possibility of cross-reactivity of T cells triggered against a pathogen-
derived peptide containing the “DERAA”-sequence, i.e. from Influenza A, with the 
“DERAA”-containing peptide derived from vinculin is demonstrated in DQ8-
transgenic mice. It is important to know whether “DERAA”-specific T cells are 
triggered when a mouse or individual is infected with a “DERAA”-containing strain of 
the Influenza A virus. Furthermore, extensive studies for cross-reactivity of other 
pathogen-derived “DERAA”-containing peptides with the vinculin-peptide have to be 
performed both in mice and in humans. An extensive meta-analysis for the effect of 
“DERAA”-containing HLA-DRB1 alleles in other diseases and infections can probably 
help to elucidate the underlying mechanism. 
An extensive family study in which individuals from three generations can be studied 
possibly will give more insight in the mechanism underlying the observed effect of 
“DERAA”-containing HLA-DRB1 alleles as a NIMA. It is important to know in which 
immunological status the acquirement of “DERAA”-containing antigens can still lead 
to a protective effect; is it necessary to acquire this NIMA in a fetal stage or is 
induction of the effect still possible when acquired in adulthood? The latter would have 
implications to treat “DERAA”-negative individuals with “DERAA”-containing 
molecules (e.g. by means of transfusing cells expressing the “DERAA”-containing 
HLA-DRB1 molecules) to induce protection against the development of RA in 
individuals who are at risk or ameliorate existing disease in “DERAA”-negative 
patients. 
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When more is known about the fine-specificity of ACPA, the interplay between T cells 
and their help to ACPA-producing B cells can be studied in more detail. This both 
accounts for “citrulline”-specific T cells and for T cells specific for a connected protein 
(e.g. vinculin) helping an ACPA-producing B cell. Since these studies rely on a 
delicate choice of at least HLA-type, ACPA-status and ACPA-specificity, large cohorts 
are necessary to perform these studies. 
Both for the C1858T polymorphism of the PTPN22 gene and the CD40 SNP, 
functional studies are necessary to study what the precise effects are of the nucleotide 
change and whether the already studied SNPs are the most informative or whether they 
are in linkage disequilibrium with another SNP that is the causative SNP for the 
functional effect. After this, the cell type important for the observed effect has to be 
defined. 
 
In conclusion, several different aspects playing a role in the pathogenesis of RA were 
studied in this thesis. Answers were found, opening new perspectives for further 
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Rheumatoid arthritis 
Arthritis is a group of conditions characterized by joint inflammation. This 
inflammation can be caused by different mechanisms (e.g. autoimmunity, fractures, 
wearing, or infection) and can lead to breakdown of the cartilage in the joints. 
Rheumatoid arthritis (RA) is a chronic inflammation of several joints caused by 
autoimmunity. The diagnosis of RA is based on a list of seven criteria: morning 
stiffness, arthritis of 3 or more joint areas, arthritis of hand joints, symmetric arthritis, 
rheumatoid nodules, serum rheumatoid factor and radiographic changes. Since only 
four of these seven ACR criteria have to be fulfilled for the diagnosis of RA, the RA 
patient population is clinically heterogeneous. The occurrence of RA varies among 
countries and areas over the world; in Europe it has a prevalence of approximately 1% 
within the Caucasian population. In the Dutch population, women are affected by RA 
approximately two times more frequently than men. The progression of the disease is 
often measured by making x-rays of the joints (e.g. each year) in addition to 
assessments of physical function and questionnaires. The mechanism of RA 
development is complex and largely unknown, but it is generally accepted that both 
genetic and environmental factors play a role. In this thesis, on the one hand,  factors 
involved in the protection against RA are studied. On the other hand, processes and 
genetic factors involved in the severity of RA and an increased risk of RA development 
have been investigated. In this summary several basic immunological aspects will be 
discussed and all chapters will be discussed briefly. 
The immune system 
The immune system is comprised of cells involved in adaptive and innate immune 
responses, each cell exerting his own function. Adaptive immune responses are 
characterized by the fact that they are antigen-specific immune responses of cells 
having a receptor specific for the antigen it responds to, which are the T cell receptor 
and B cell receptor in this case. When a B cell recognizes the antigen with its B cell 
receptor, this can result in the production of antibodies. An antibody is a protein that 
binds specifically to its corresponding antigen and thereby pathogens are neutralized or 
prepared for uptake and destruction by phagocytes. Adaptive immune responses occur 
during lifetime and involve specific antigen recognition and expansion of B and T 
cells. This distinguishes such responses from innate immunity, which includes the 
engulfment and digestion of pathogens by phagocytic cells that are immediately 
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pathogens and not against an individual pathogen. Innate and adaptive immune 
responses are interdependent, and are exerted mainly by white blood cells (leukocytes). 
The different cells from the  immune system all exert their own function. Antigen 
presenting cells (APC), e.g. dendritic and B cells, scan the whole body for its content, 
both self-proteins and infectious agents. They can take up these proteins, cut them in 
pieces (called peptides) and present these peptides via what is called a HLA molecule 
to a T cell (Figure 1). These HLA molecules are the most important genetic risk factor 
involved in RA development. Regarding the risk of RA development, three variants 
can be discriminated; either by a variant that increases the risk of RA development 
(called shared epitope (SE)), or by a variant that gives a lower chance of RA 
development (called DERAA), or by a neutral variant that does not have an influence 







Figure 1. Presentation of a 
peptide to a T cell by an 
antigen presenting cell (APC). 
The peptide is presented bound 
in a HLA molecule to the T 
cell via its specific receptor. 
 
Protection by “DERAA” 
Different individuals can have different HLA molecules. Each variant has a slightly 
different composition of the building blocks, called amino acids, it consists of. There 
are 20 different amino acids which can be indicated with a one letter code. The variants 
containing at a specific position the amino acids that are coded by the letters 
“DERAA”, give an individual a lower chance to develop RA. This effect had been 
described already, but we describe in  Chapter 2 and Chapter 3 of this thesis that a 
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protection to her child against the development of RA both with and without passing 
the gene responsible for this HLA molecule to the child. This in contrast to a father that 
has a DERAA-containing HLA molecule. The father can only confer protection to the 
child when his DERAA-containing HLA molecule is inherited by the child. 
Vimentin-specific T cells 
RA patients can develop different kinds of antibodies, from which some can react 
against proteins from the body which have a little difference compared to the regular 
protein. This change is called citrullination and therefore these antibodies are called 
anti-citrullinated protein antibodies (ACPA). Citrullination is a common natural 
process present in all individuals, but only RA patients can develop these antibodies. 
One of the proteins these antibodies can react to is vimentin. This is a self-protein that 
is present in every cell of an individual. B cells can receive signals from activated T 
cells to produce antibodies. In Chapter 4 of this thesis it was studied whether we could 
identify the peptides from the vimentin protein which an APC presents to a T cell to 
activate this T cell. We were especially interested in Citrulline-specific T cell 
responses. This identification was performed with the help of HLA-transgenic mice 
expressing a human HLA-molecule on their cells. Two peptides inducing a Citrulline-
specific T cell response were identified. The cells from 10 RA patients and 5 healthy 
controls were tested for reactivity against these two peptides. Several RA patients 
showed a Citrulline-specific response, which was absent in the 5 healthy controls. 
Since the amount of tested individuals was small, more extensive studies have to be 
performed to identify the presence/absence of T cell responses in different groups of 
individuals. 
PTPN22 and CD40 
Next to HLA molecules there are several other genetic factors involved in the risk of 
RA development. In this thesis, two of these genes are studied. They are called 
PTPN22 and CD40. 
The sequence of building blocks of a gene, called nucleotides, can differ between 
different individuals in a population. When the frequency of a single nucleotide change 
is equal or higher than 1%, this is called a single nucleotide polymorphism (SNP). The 
most studied SNP of the PTPN22 gene is associated with RA and several other auto-
immune diseases. There were indications that there is also a relation between this SNP 
of the PTPN22 gene and the development of ACPA antibodies. We investigated in 
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development of RA when information about the PTPN22 gene is combined with 
presence/absence of ACPA antibodies. The analyses showed that both information on 
the PTPN22 SNP and the presence/absence of ACPA can help to predict the 
development of RA, but both factors combined do not result in additive value for 
prediction. 
 
Because nowadays, RA patients are seen in an earlier phase of the disease, before the 
appearance of well established indicators of poor prognosis such as erosions and 
nodules, markers which have a good predictive value on radiographic damage in an 
early phase of the disease will become more important. Therefore, we investigated in 
Chapter 6 whether different SNPs, including one in the CD40 gene, are involved in 
the progression and severity of RA once patients are diagnosed. It was shown that the 
SNP of the CD40 gene was indeed associated with the severity and progression of RA. 
The CD40 gene encodes a molecule, CD40, that is involved in the interactive signaling 
between B and T cells to activate them. Further studies have to show the functional 
effects of the SNP in the CD40 protein. 
 
The studies included in this thesis are quite diverse but all deal with different aspects 
playing a role in RA development or progression of the disease. Several questions have 
been answered, but all result in a range of new questions that need to be answered in 
future studies. I hope this summary will explain a little bit the struggles I have been 
trying to answer in the last 5 years. Of course everybody is invited to read the detailed 
versions of each article in the indicated chapters! 
 
 




Artritis is een groep van verschillende aandoeningen die worden gekarakteriseerd door 
gewrichtsontsteking. Deze ontsteking kan worden veroorzaakt door verschillende 
mechanismen, bijv. autoimmuniteit (de ontsteking is gericht tegen eiwitten/cellen van 
het eigen lichaam), breuken, slijtage of infectie en kan leiden tot de afbraak van het 
kraakbeen dat zich in de gewrichten bevindt. De diagnoses van de verschillende 
vormen van artritis worden gesteld aan de hand van ziektecriteria. Reumatoïde artritis 
(RA) is een chronische ontsteking van verschillende gewrichten veroorzaakt door een 
autoimmuun-reactie. De diagnose ervan is gebaseerd op een lijst van zeven 
symptomen: ochtendstijfheid, artritis aan 3 of meer gewrichten, artritis van de hand-
gewrichten, symmetrie van de artritis, reumatoïde nodules, positief voor reumafactor 
(bepaald antilichaam) en veranderingen in de gewrichten die te zien zijn op 
röntgenfoto’s. Als er aan minstens vier van deze symptomen wordt voldaan, wordt de 
diagnose RA gesteld. Dit betekent dat twee verschillende personen met RA maar één 
symptoom overeenkomstig hoeven te hebben en verder hele verschillende klachten 
laten zien. De ernst van het verloop van RA wordt vaak gemeten door elk jaar 
röntgenfoto’s te maken naast het lichamelijk onderzoek en vragenlijsten. In 
verschillende landen is de mate waarin RA voorkomt verschillend, maar in de landen 
binnen Europa heeft ongeveer 1% van de Caucasische populatie RA. Van de patiënten 
met RA in Nederland is het percentage vrouwen twee keer zo groot als het percentage 
mannen. De ontwikkeling van de ziekte is complex en het verloop ervan nog 
onduidelijk, maar onderzoek heeft aangetoond dat erfelijke en omgevingsfactoren een 
rol spelen. In dit proefschrift wordt enerzijds naar factoren gekeken die bescherming 
geven tegen de ontwikkeling van RA en anderzijds juist naar processen en factoren die 
een rol spelen in de (versnelde) ontwikkeling of verergering van RA. In deze 
samenvatting zullen eerst een aantal aspecten van het immuunsysteem worden 
besproken en vervolgens zal er kort worden ingegaan op de onderwerpen en 
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Het afweersysteem 
Ons afweersysteem bestaat uit verschillende soorten cellen die elk hun eigen rol spelen 
in het ontwikkelen van een ontsteking of afweerreactie. Globaal kan het afweersysteem 
worden onderverdeeld in een specifiek en aangeboren afweersysteem. De reacties van 
het specifieke afweersysteem worden getypeerd door het feit dat de reactie specifiek 
gericht is tegen een bepaald stukje eiwit, een antigeen genoemd. Deze antigenen 
worden door zogenoemde B-cellen herkend met de B-cel receptor en door T-cellen met 
de T-cel receptor. In het geval van een B-cel leidt de herkenning van het antigeen tot de 
productie van antilichamen door de B-cel. Een antilichaam is een beschermingsstof die 
in een organisme wordt gevormd als specifieke reactie op een antigeen. Het 
antilichaam bindt aan het antigeen dat hij herkent, wat vervolgens resulteert in het 
onschadelijk maken van de cel of het eiwit waarvan dit antigeen van afkomstig is. Als 
eenmaal een reactie is opgetreden tegen een bepaald antigeen, dan blijven er levenslang 
B of T-cellen aanwezig in het lichaam die specifiek tegen dit antigeen kunnen reageren 
als ze het opnieuw tegenkomen in het lichaam. Dit onderscheidt de cellen die 
betrokken zijn bij specifieke afweerreacties van cellen van het aangeboren 
immuunsysteem. Bij reacties van het aangeboren immuunsysteem worden 
ziekteverwekkers door cellen van het afweersysteem die altijd beschikbaar zijn 
‘opgegeten’ (fagocytose genoemd). Deze cellen kunnen dan vervolgens deze 
ziekteverwekkers afbreken in de cel en daarmee de ziekteverwekker voor het lichaam 
opruimen. De reacties van het aangeboren afweersysteem zijn gericht tegen moleculen 
en eiwitten die in veel verschillende ziekteverwekkers voorkomen en niet tegen een 
molecuul dat specifiek voor één virus of bacterie is. De cellen van het aangeboren en 
specifieke immuunsysteem behoren vrijwel allemaal tot de ‘witte’ bloedcellen 
(leukocyten en lymfocyten) en werken samen om een optimale afweerrespons te 
krijgen. In dit proefschrift is onderzoek gedaan aan de zogenoemde T en B-cellen die 
onderdeel uitmaken van het specifieke afweersysteem.  
Zoals hierboven al is beschreven, heeft elke cel van het afweersysteem zijn eigen 
functie. Zo zijn er de antigeen-presenterende cellen (bijvoorbeeld B-cellen en 
dendritische cellen), die het hele  lichaam doorreizen en daarbij aftasten wat er allemaal 
in het lichaam aanwezig is, zowel alles wat er hoort te zitten als eventuele 
ziekteverwekkers. Zij kunnen deze cellen of eiwitten dan opnemen, in stukjes knippen 
en vervolgens als een soort ober, de gevonden stukjes eiwit (peptides), op een dienblad 
(een HLA-molecuul in de mens) aan T-cellen presenteren (Figuur 1). Deze HLA-
moleculen zijn de belangrijkste genetische risico factor voor de ontwikkeling van RA. 
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Met betrekking tot het risico voor de ontwikkeling van RA, zijn er drie varianten van 
de HLA-moleculen; een variant die het risico op de ontwikkeling van RA verhoogt (die 
wordt de ‘Shared Epitope’ (SE) genoemd), een variant die de kans op de ontwikkeling 
van RA verlaagt (“DERAA” genoemd) en een variant die geen (beschreven) invloed 










Figuur 1. Presentatie van een 
stukje eiwit (peptide) door een 
antigeen presenterende cel 
(APC) aan een T-cel. Het 
peptide wordt gepresenteerd 
door een HLA-molecuul op de 
APC aan de bijpassende T-cel 
receptor die aanwezig is op de 
T-cel. 
 
Bescherming door “DERAA” 
Verschillende individuen hebben verschillende HLA moleculen. De bouwstenen 
waaruit een HLA-molecuul bestaat heten aminozuren. Er zijn 20 verschillende 
aminozuren en elk type HLA-molecuul heeft een net andere samenstelling van deze 
aminozuren. Deze aminozuren kunnen met een éénletterige code worden aangegeven. 
De varianten van de HLA-moleculen die de aminozuren gecodeerd door “DERAA” 
bevatten, geven een bescherming tegen de ontwikkeling van RA. Dit effect was reeds 
beschreven bij de start van mijn promotie, maar daarnaast is gebleken dat als een 
moeder een “DERAA”-bevattend HLA-molecuul heeft, zij haar kind bescherming 
meegeeft voor de ontwikkeling van RA ongeacht of zij het “DERAA”-molecuul 
genetisch aan haar kind doorgeeft of niet. Dit geldt alleen voor de moeder en niet voor 
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kind zijn “DERAA”-bevattende HLA-molecuul erft. Dit onderzoek staat beschreven in 
hoofdstuk 2 en hoofdstuk 3 van dit proefschrift.  
 
Vimentine-specifieke T-cellen 
RA patiënten kunnen verschillende soorten antilichamen vormen, waaronder 
antilichamen die gericht zijn tegen eiwitten die een kleine verandering hebben 
ondergaan ten opzichte van het ‘gewone’ lichaamseigen eiwit. Deze verandering wordt 
aangeduid met citrullinatie en de antilichamen worden daarom “anti-Citrullinated 
protein antibodies” (ACPA) genoemd. Citrullinatie is een proces dat in ieder individu 
optreedt, maar alleen RA patiënten maken antilichamen tegen deze eiwitten. Eén van 
de eiwitten waar deze antilichamen tegen kunnen reageren is vimentine. Vimentine is 
een lichaamseigen eiwit dat aanwezig is in elke cel van het lichaam. Antilichamen 
worden geproduceerd door B-cellen als deze B-cellen signalen krijgen van 
geactiveerde T-cellen om antilichamen te gaan produceren. In hoofdstuk 4 van dit 
proefschrift is onderzocht of we konden ontdekken tegen welk stukje van het 
veranderde vimentine-eiwit T-cellen kunnen reageren en of ze dan ook specifiek zijn 
voor het veranderde eiwit of ook tegen het ‘normale’ vimentine kunnen reageren. We 
hebben hiervoor gebruik gemaakt van een bepaald soort muizen die menselijke HLA-
moleculen op hun antigeen presenterende cellen tot expressie brengen zodat we de 
bijpassende peptides voor de humane situatie konden onderzoeken. In deze studie zijn 
twee peptides geïdentificeerd waarbij de T-cellen van de gebruikte muizen specifiek 
reageerden tegen de veranderde (gecitrullineerde) vorm van het peptide en niet tegen 
het onveranderde peptide. Vervolgens hebben we met cellen van RA patiënten en 
gezonde controles gekeken of deze ook tegen de geïdentificeerde peptides konden 
reageren. De T-cellen van een aantal RA patiënten reageerden specifiek tegen het 
gecitrullineerde peptide en de cellen van gezonde proefpersonen lieten geen reactie 
tegen dit peptide zien. Omdat er slechts 10 RA patiënten en 5 gezonde controle 
personen zijn getest, moet er een veel uitgebreider onderzoek worden gedaan naar het 
voorkomen van dit soort T-cellen in verschillende groepen personen. 
 
PTPN22 en CD40 
Naast HLA-moleculen zijn er een aantal andere genetische factoren die de kans om RA 
te ontwikkelen beïnvloeden. In dit proefschrift zijn twee van deze genetische factoren 
nog wat verder bestudeerd. Dit zijn CD40 en PTPN22. 
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De volgorde van de bouwstenen van een gen, die nucleotiden worden genoemd, kan 
verschillend zijn bij verschillende individuen in een populatie. Als de mate waarin een 
bepaalde variant voorkomt gelijk of hoger is dan 1% wordt zo’n variant een ‘single 
nucleotide polymorphism’ (SNP) genoemd. De meest bestudeerde SNP van het 
PTPN22 gen is geassocieerd met RA maar ook met een aantal andere auto-
immuunziekten. Er lijkt een relatie te zijn tussen deze SNP en de ontwikkeling van de 
hiervoor beschreven ACPA antilichamen. In hoofdstuk 5 van dit proefschrift is 
onderzocht wat de voorspellende waarde op de ontwikkeling van RA is van informatie 
over de SNP van het PTPN22 gen, het wel/niet hebben van ACPA, of informatie over 
beide. Hieruit blijkt dat afzonderlijke informatie over of de SNP of het wel/niet hebben 
van ACPA kan helpen bij de voorspelbaarheid van de ontwikkeling van RA, maar 
informatie over beide heeft geen aanvullende waarde. Dit betekent dat deze twee 
genetische factoren betrokken zijn bij dezelfde route voor de ontwikkeling van RA. 
 
Tegenwoordig komen toekomstige RA patiënten  al voordat zij genoeg symptomen 
hebben om een goede diagnose te kunnen stellen bij de dokter. Naast een vroege 
diagnose zou het heel waardevol zijn om te kunnen voorspellen of iemand met RA een 
ernstige vorm van RA gaat krijgen of dat het een vorm is met een veel langzamer 
verloop. Om op dit moment toch een goede diagnose en een daarmee samenhangend 
behandelplan op te kunnen stellen is het belangrijk om hiervoor nieuwe voorspellende 
factoren te identificeren. Daarom hebben we in hoofdstuk 6 bestudeerd of een aantal 
SNPs waarvan is beschreven dat ze een invloed hebben op de ontwikkeling van RA 
ook invloed hebben op het verloop van de ziekte wanneer deze al gediagnosticeerd is. 
We vonden dat één van deze SNPs, een variant in het gen voor CD40, inderdaad van 
invloed is op de progressie van de ziekte. CD40 is een molecuul dat op het oppervlak 
van een B-cel voorkomt en een belangrijke rol speelt in de communicatie tussen een B-
cel en een T-cel wat kan resulteren in de activatie van de B-cel. 
 
Zoals waarschijnlijk al is opgevallen, zijn er een aantal verschillende aspecten die een 
rol spelen in de ontwikkeling van RA en de progressie daarvan onderzocht in dit 
proefschrift. De resultaten hebben een aantal facetten verduidelijkt, maar roepen zeker 
ook nog vele onopgeloste vragen op die door vervolgstudies opgelost moeten worden. 
Ik hoop dat deze samenvatting velen van jullie een beetje een idee geeft waar ik me de 
afgelopen 5 jaar mee bezig heb gehouden. En natuurlijk zijn jullie van harte 
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List of abbreviations used in this thesis 
ACPA  anti-citrullinated protein antibody 
ACR  American College of Rheumatology 
DERAA five amino acids present in certain HLA-DRB1 molecules 
EAC  early arthritis cohort 
ELISA  Enzyme linked immunosorbent  assay 
FACS  Fluorescent activated cell sorter 
GWAS  genome wide association study 
HLA  human leukocyte antigen 
IFN  interferon- 
Ig  Immunoglobulin 
NIMA  non-inherited maternal antigen 
NIPA  non-inherited paternal antigen 
PBMC  Peripheral blood mononuclear cells 
PTPN22 protein tyrosine phosphatase N22 
RA  rheumatoid arthritis 
SE  shared epitope 
SNP  single nucleotide polymorphism 
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